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The Radiological Physics Center (RPC) uses both on-site and remote reviews to credential
institutions for participation in clinical trials. Anthropomorphic quality assurance (QA) phantoms are
one tool the RPC uses to remotely audit institutions, which include thermoluminescent dosimeters
(TLDs) and radiochromic film. The RPC desires to switch from TLD as the absolute dosimeter in the
phantoms, to optically stimulated luminescent dosimeters (OSLDs), but a problem lies in the angular
dependence exhibited by the OSLD. The purpose of this study was to characterize the angular
dependence of OSLD and establish a correction factor if necessary, to provide accurate dosimetric
measurements as a replacement for TLD in the QA phantoms. A 10 cm diameter high-impact
polystyrene spherical phantom was designed and constructed to hold an OSLD to study the angular
response of the dosimeter under the simplest of circumstances for both coplanar and non-coplanar
treatment deliveries. OSLD were irradiated in the spherical phantom, and the responses of the
dosimeter from edge-on angles were normalized to the response when irradiated with the beam
incident normally on the surface of the dosimeter. The average normalized response was used to
establish an angular correction factor for 6 MV and 18 coplanar treatments, and for 6 MV noncoplanar treatments specific to CyberKnife. The RPC pelvic phantom dosimetry insert was modified
to hold OSLD, in addition to the TLD, adjacent to the planes of film. Treatment plans of increasing
angular beam delivery were developed, three in Pinnacle v9.0 (4-field box, IMRT, and VMAT) and
one in Accuray’s MultiPlan v3.5.3 (CyberKnife). The plans were delivered to the pelvic phantom
containing both TLD and OSLD in the target volume. The pelvic phantom was also sent to two
institutions to be irradiated as trials, one delivering IMRT, and the other a CyberKnife treatment. For
the IMRT deliveries and the two institution trials, the phantom also included film in the sagittal and
coronal planes. The doses measured from the TLD and OSLD were calculated for each irradiation,
and the angular correction factors established from the spherical phantom irradiations were applied to
the OSLD dose. The ratio of the TLD dose to the angular corrected OSLD dose was calculated for
each irradiation. The corrected OSLD dose was found to be within 1% of the TLD measured dose for
all irradiations, with the exception of the in-house CyberKnife deliveries. The films were normalized
iv

to both TLD measured dose and the corrected OSLD dose. Dose profiles were obtained and gamma
analysis was performed using a 7%/4 mm criteria, to compare the ability of the OSLD, when
corrected for the angular dependence, to provide equivalent results to TLD. The results of this study
indicate that the OSLD can effectively be used as a replacement for TLD in the RPC’s
anthropomorphic QA phantoms for coplanar treatment deliveries when a correction is applied for the
dosimeter’s angular dependence.
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Chapter 1 Introduction
1.1 Statement of Problem
The current standard of practice for mailable anthropomorphic quality assurance (QA)
phantoms for the purpose of remote audits by the Radiological Physics Center (RPC) includes the use
of thermoluminescent dosimeters (TLD) as an absolute dosimeter within the phantom. The TLD have
been shown to be able to identify calibration errors greater than 5%, and to have an accuracy similar
to ion chamber measurements with a high degree of precision1. There are several downsides to using
TLD for remote audits, however, including a long wait period following irradiation before being read,
temperature and humidity dependence, destruction of signal after a single reading, and a long reading
time. The RPC has already made the switch from TLD to optically stimulated luminescence
dosimeters (OSLD) in 2010 for remote external beam output monitoring. The benefits of OSLD
include lower cost, a shorter wait period following irradiation, simpler readout procedures, minimal
energy dependence, they are reusable, can be re-read, and they are not affected by changes in
temperature and humidity. The use of OSLD for this purpose has been well studied and validated by
the RPC, and under reference conditions, has been shown to agree well with both ion chamber and
TLD measurements for both photon and electron irradiations2. The switch from TLD to OSLD in the
anthropomorphic QA phantoms is also desirable, for the same reasons as stated above. However, the
use of OSLD in the RPC’s anthropomorphic phantoms has not been studied for evaluation of special
treatment techniques, nor for credentialing of institutions to participate in National Cancer Institute
(NCI) sponsored clinical trials.
The problem with implementing the OSLD in the anthropomorphic phantoms lies in the
angular dependence exhibited by the dosimeters. Kerns et al.3 demonstrated a decreased response of
the nanoDot OSL dosimeter of 4% and 3% for 6 MV and 18 MV beams incident parallel to the plane
of the dosimeter, respectively. For a radiation treatment with multiple fields at different gantry
angles, some or all of the beams could be oriented such that the OSLD demonstrate the decreased
angular response. The magnitude of the angular response could potentially be important and should
be accounted for in the calculation of dose. This observed under-response of the OSLD was
attributed to the non-uniform geometry of the nanoDot dosimeter. A lower fluence of the primary
beam is incident on the disk shaped sensitive volume of the dosimeter from an edge-on orientation,
which causes the majority of the dose at that orientation to be from scattered photons and low energy
Compton electrons. The stopping power ratio of the sensitive material relative to water decreases
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with decreasing electron energy, so as compared to the dose deposited in a face
face-on
on orientation from
higher energy electrons, the dose deposited by the lower energy electrons would be less.
In order to investigate the applicability of the OSLD and their angular dependence for use in
the anthropomorphic QA phantoms
phantoms,, the RPC’s pelvic phantom was chosen because of its simplicity
in design, ease with which it could be modified, and it has been shown to verify treatments with
wi a
high level of precision4. This study aims to characterize the angular dependence of OSLD in the
pelvic phantom for effectively utilizing the dosimeters as a replacement for TLD in the RPC’s
anthropomorphic quality assurance phantoms.

1.2 Radiological Physics Center
The Radiological Physics Center (RPC) was founded in 1968 and has been continuously
funded by the NCI. The mission of the RPC is to ensure that institutions participating in NCI funded
cooperative clinical trial groups deliver clinically comparable and consistent radiation therapy
treatments. The RPC monitors the radiation therapy programs of each institution by on-site
on
dosimetry
reviews and remote audits. The tools for remote audit qquality checks include mini-phantoms
phantoms
containing either OSLD or TLD for the purpose of machine output checks, and mailable
anthropomorphic QA phantoms.

Figure 1.1 Anthropomorphic QA phantoms: prostate (upper left), thorax (upper right), IMRT head
and neck (lower left), SBRT spine (upper middle), SRS head (lower middle), and SBRT liver (lower
right)
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The RPC has five anthropomorphic QA phantom designs
designs, shown above in Figure 1.1:
1.1 a
stereotactic radiosurgery (SRS) head, stereotactic body radiotherapy (SBRT) liver, pelvic-prostate,
pelvic
intensity modulated radiotherapy (IMRT) head & neck, a thorax-lung phantom and an SBRT spine
phantom. The QA phantoms are design
designed to be light-weight
weight and durable for ease of mailing, to have
a phantom exterior that approximates the size and shape of the average patient, contain targets as well
as organs at risk, heterogeneities, dosimeters to evaluate the treatment delivery, and the phantoms are
constructed of materials that simulate patient CT densities4. The anthropomorphic
omorphic QA phantoms
assess the radiotherapy treatment process from imaging to dose delivery to achieve a more
mor
comprehensive picture of the ability of the institution to del
deliver
iver dose for special treatment techniques
and for credentialing institutions participating in clinical trials. These phantoms were irradiated
nearly 500 times last year, as shown in Figure 1.2. Currently, the dosimeters used in the QA
phantoms include TLD for absolute point dose measu
measurements
rements in the targets and critical structures, and
radiochromic film in two planes of the phantom in order to measure the dose distributions. The
Th dose
profiles from the film are normalized to the TLD dose.

Figure 1.2 RPC phantoms mailed per year

1.3 Optically
ptically Stimulated Luminescence
1.3.1 OSL Phenomenon
The phenomenon behind optically stimulated luminescence (OSL) is the same as that behind
the TL process, with the stimulation method being exposure to light, rather than the application of
3

heat. The model consists of two energy levels, the valence and conduction bands, which are
separated by a forbidden region. Defects purposefully introduced into the crystalline structure of the
material establish local energy levels within the forbidden region, which are called traps. Exposure to
ionizing radiation excites the electrons to the conduction band and the holes left behind move to the
valence band, creating electron-hole pairs. The electrons that have been excited to the conduction
band and the holes in the valence band can move freely within the crystal lattice. The electrons will
stay in the conduction band until they move back to the valence band and recombine with a hole, or
are captured by an energy trap in the forbidden region5. The electrons that have been captured by
energy traps cannot recombine with a hole without first being stimulated. Exposing the material to
light stimulates the trapped electrons back to the conduction band, from where they can recombine
with holes. This recombination of an electron-hole pair creates an excited state of the recombination
center, and results in luminescence. A process of hole capture can occur, where a hole in the valence
band can combine with an F-center to create additional recombination sites6.
Depending on the energy level of the trap within the forbidden region, the trap can be either a
dosimetric, shallow, or a deep trap. The dosimetric traps are deep enough to keep charge from
spontaneously escaping at room temperature, but they are shallow enough that the charge contained
can escape by exposing the material to visible light. These dosimetric traps are responsible for the
luminescence measured in OSL dosimetry. Ideally, the amount of charge captured within the
dosimetric traps is proportional to the absorbed dose of the crystal. Traps that are close in energy to
either the conduction band or the valence band are called shallow electron traps and shallow hole
traps, respectively. Deep electron traps and deep hole traps also exist within the forbidden region,
further in energy from the conduction band for the electron traps, and further from the valence band
for hole traps. Yukihara and McKeever5 describe the influence of charge capture by both the shallow
and deep traps on the OSL signal. Shallow traps are associated with phosphorescence directly
following irradiation, as well as after exposure to light. Directly following irradiation, charges from
shallow traps escape and recombine, releasing luminescence. Phosphorescence after optical
stimulation occurs when charges from dosimetric traps escape, but then are captured by shallow traps.
Another important process associated with shallow traps is the initial increase in signal intensity when
the material is exposed to light. At the beginning of the stimulation, a large number of shallow traps
are available and can trap charge coming from the dosimetric traps, but as stimulation continues,
these shallow traps become filled and more of the charges escaping from dosimetric traps will
recombine and release light. Deep electron and deep hole traps affect the sensitivity of the material
by competing with the recombination process, both during irradiation as well as stimulation. The
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deep traps may capture charge that has escaped the dosimetric traps, but as the deep traps fill, more
electrons recombine and contribute to the OSL signal. This process causes the dosimeter to have a
dependence on the history of irradiation, due to a residual signal from previous irradiations that can
be difficult to remove from the crystal.
The shape of the luminescence curve versus time can be modeled by an exponential decay, if
stimulated by a continuous exposure to light of the appropriate wavelength. The concentration of the
shallow and deep traps will affect the OSL curve, but the simplest approach is to assume that the
electrons do not fall into another trap after escaping the dosimetric trap, and they are allowed to
recombine. The light resulting from the recombination of the electron-hole pair is collected to create
the luminescence curve, and the integral of this curve is proportional to the total absorbed dose of the
material.
1.3.2 Properties of Al2O3:C Dosimeters
The material most commonly used in commercial optically stimulated luminescence
dosimeters is carbon-doped aluminum oxide (Al2O3:C). This material was originally investigated as a
material for thermoluminescence (TL) dosimetry, with approximately 60 times higher TL sensitivity
than LiF:Mg,Ti7, but when it was shown that the TL signal was susceptible to light exposure, the
material was implemented as an optically stimulated luminescence dosimeter. A low effective atomic
number is a desirable characteristic in a material used for dosimetry; however, the higher effective
atomic number of aluminum oxide, 11.288, leads to an increase in energy dependence of the
dosimeter, especially at lower energies, that must be accounted for if used to be an accurate radiation
dosimeter.
Al2O3:C can be produced as single crystals, or as powders of varying grain sizes. The
crystals are grown in an atmosphere that prevents oxidation keeping the presence of oxygen low, and
introducing carbon. This atmosphere creates a high concentration of stable oxygen vacancies and
defects in the crystal lattice. When the oxygen vacancy is filled by two electrons, a neutral F-center is
created. If the oxygen vacancy is filled with a single electron, a positively charged F+-center is
created. These F and F+ centers contribute greatly to the luminescence sensitivity of the material, and
are present in aluminum oxide in concentrations of 1017 cm-3 and 1015-1016 cm-3, respectively9.
Electrons that have escaped traps recombine with the F+-centers, creating excited F-centers, which
then relax back to the ground state by emitting luminescence5,9. F-center emission is centered at 420
nm with a lifetime of 35 ms at room temperature, and F+-centers produce luminescence at 330 nm
with a much shorter lifetime of less than 7 ns10.
5

An advantage of carbon-doped aluminum oxide is the wide energy forbidden region, 9.5
10

eV , which allows the local energy levels in the band gap to be distant enough from the conduction
band to be thermally stable. If the gap between the valence and conduction bands is too narrow, the
traps are too shallow to hold charge at room temperature for any length of time. Another advantage
of the material is its uniformity in sensitivity and properties, due to having a homogeneous mixture of
different crystal sizes5. The main disadvantage of the material is the residual charge that is stored in
the deep traps, which need more than optical bleaching to be removed. According to Reft11, for
absorbed doses up to 2 Gy, optical bleaching will remove virtually all the signal without changing the
sensitivity of the material, but for doses above 2 Gy, annealing with fluorescent lights does not
remove all trapped charges. However, annealing with a tungsten-halogen lamp (THL) for 3 minutes
will remove the signal. It has also been shown that annealing the dosimeters with high temperatures
will empty the traps of all charges12, but dosimeters enclosed in plastic cannot withstand the high
temperatures necessary.
The response and measured signal is dependent on characteristics of the material and the
reader system, such as energy dependence, fading, linearity, and depletion. The Al2O3:C dosimeter
characteristics have been previously studied, and will be briefly outlined here. The energy
dependence of the OSLD was investigated in Viamonte et al.13, and it was shown that when
dosimeters are calibrated using a 60Co beam there is a 4% decrease in the sensitivity for higher
energies, making it necessary to apply a correction factor. The response of the OSLD has been shown
to have no dependence on dose rate13,14. Jursinic15 investigated the changes in the dosimetric
characteristics of the OSLD with accumulated dose, finding that dosimeters with greater accumulated
dose experience a greater degree of supra-linearity. He suggested that dosimeters that are to be used
multiple times, repeating the cycle of annealing, irradiating and reading, could make measurements
with high precision if the individual OSLD are characterized after each annealing to account for
changes with accumulated dose. Aguirre et al.16 have reported that the characteristics of individual
dosimeters need not be investigated after each annealing, and is independent of the number of cycles
it has been irradiated and annealed, provided the accumulated dose to the dosimeter is less than 10
Gy. It has been shown that up to an accumulated dose of 20 Gy, the sensitivity of the OSLD remains
the same, but above 20 Gy the sensitivity decreases by approximately 4% with every 10 Gy additional
accumulated dose11,17. The linearity of the OSL response for an irradiation has been studied
extensively, and it has been shown that the response of the dosimeter is linear up to a delivered dose
of approximately 2 - 4 Gy11,13,14,17,18, with supra-linearity observed at higher doses. An explanation
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for the observed supra-linearity was given by Jursinic17, attributing the response to the competition of
the deep traps described in Section 1.3.1.
An initial rapid decay of the signal that has been observed in OSLD, called the transient
signal, is due to spontaneously escaping charges from the shallow traps without optical stimulation.
The decay of the transient response affects the initial intensity of the signal, but does not greatly
affect the total area under the luminescence versus time curve19. Several studies have shown that
after 8 minutes, the transient signal has decayed and the signal is stable11,17,20. Perks et al.20 reported a
2% decay in the signal from 10 minutes to 60 hours post-irradiation, and Jursinic17 observed stability
in the signal to be within 2% at 2.5 days after irradiation. Viamonte et al.13 reported no loss of signal
within the first six hours after irradiation, a 2 % signal loss within the first five days, and a stable
signal from five days to 21 days post-irradiation. Schembri and Heijmen14 observed a fading of the
OSL signal of less than 1.8% over a 3 week time period. Needless to say, the fading characteristics of
the OSLD have been studied exhaustively and the conclusion is that this effect should be accounted
for in the measurement of dose.
The temperature dependence of the OSL has also been investigated and was shown to not
affect the response of the dosimeters for a temperature range of 10° to 40 °C17. Each reading of a
dosimeter decreases the stored charge by a finite amount. A depletion of the OSL signal with each
reading of 0.05% has been reported17, and other works have suggested that 0.2% of the signal is lost
with each reading13,16.
Jursinic17 found that when OSL are used repeatedly, going through many cycles of
irradiation, reading, and annealing, the measurement uncertainty was 0.6%, demonstrating an
improvement in the precision over using the dosimeter a single time. He reported that for the singleuse method, the measurement uncertainty was 0.9%. Yukihara et al.18 reported a similar level of
uncertainty, 0.7%, for dosimetry in radiotherapy using Al2O3:C dosimeters. The reported uncertainty
was for the readout of a single dosimeter, and the uncertainty for the readout of more than one
dosimeter would decrease with the square root of the number of dosimeters read.
1.3.3 Measurement of OSL Signal
The components necessary to stimulate and capture luminescence in OSLD include a light
source, filters, and a photomultiplier tube (PMT), as shown below in Figure 1.3. The light source is
used to stimulate the trapped charges, and a filter is necessary for the stimulation light to select the
appropriate wavelengths of light. The filtered light incident upon the dosimeter provides the energy
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necessary for the trapped charges to escape and recombine, releasing luminescence. Light in the blue
wavelengths has been found to be the most efficient for stimulating Al2O3:C dosimeter luminescence,
but green light is used instead so that the stimulation light is discernible from the F--center emission at
420 nm10. Both the stimulation light and the luminescence from the relaxation of the excited F-center
F
pass through another filter prior to entering the PMT in order to remove the stimulation photon
component. The emitted luminescence enters the PMT, where it is multiplied and counted.

Figure 1.3 Diagram of components for measuring OSLD signal. Copied with permission from
Thesis defense of Kevin Casey.
Several stimulation methods have been investigated to induce luminescence, including
continuous-wave OSL (CW-OSL)
OSL) and pulsed OSL (POSL). CW-OSL is the easiest stimulation
method and recommended most frequently. This method is performed by exposing the dosimeter to a
constantt light intensity while collecting the stimulated luminescence
luminescence.. POSL is accomplished by
exposing the material to short pulses of stimulation light with a high pulse frequency. The emitted
luminescence is then measured in between the light pulses, and not during21. This method no longer
necessitates discrimination between the stimulation and emitted light, so less filtration is needed
before the PMT. This technique requires an underst
understanding
anding of the material and the luminescence, so
that appropriate timing can be selected in order to detect most of the emitted signal and at the same
time avoid the stimulation light. The signal collected from the dosimeter is integrated over many
pulses, and if this method is performed over a longer period, the luminescence versus time curve
approximates the luminescence versus time curve for CW
CW-OSL5.
Measurement of the OSL signal can be made using the initial OSL intensity or the total OSL
signal. The initial intensity is determined using only a short exposure to the stimulation light, on the
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order of a second. Total OSL signal is determined by stimulating all the trapped charges in the
material, and this process can take a much longer time. Yukihara and McKeever5 state that the choice
of measurement technique should not matter, but that the initial OSL intensity is dependent upon the
stimulation power and is vulnerable to fluctuations in the power.

1.4 Hypothesis and Specific Aims
We hypothesized that the incorporation of OSLDs into the RPC phantoms, regardless of their
angular dependence, will measure on average equivalent dose measurements as compared to the
existing TLD measurements within ± 1%.
This hypothesis was tested with the following specific aims:
1. A dosimetry insert for the RPC pelvic phantom was modified to accommodate OSLD and
TLD adjacent to the planes of film.
2. Treatment plans of increasing angular beam delivery for the pelvic phantom were developed.
3. Each developed treatment plan was delivered three times to the pelvic phantom, containing
two TLD and two OSLD (oriented in the transverse plane) at the center of the PTV, in
addition to radiochromic film for the IMRT treatments.
4. The dose measurements from the TLD and OSLD were compared to determine dose
measurement equivalency, and whether an angular dependence correction factor was needed.
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Chapter 2 Methods and Materials
2.1 Phantoms
2.1.1 Spherical Phantom
A spherical phantom was designed and constructed in order to investigate, under the simplest
of circumstances, the magnitude of the response of the OSLD at varying angles. The 10 cm diameter
phantom pictured on the left in Figure 2.1 is made of high-impact polystyrene, with the center of the
OSLD nano-cassette positioned at the center of the sphere. A cylinder of 1 cm diameter was milled
from the base of the sphere, and an insert of the same diameter was made to fit in that space. The
cylindrical insert has a slot at the top for holding the OSL at the center of the phantom, and is attached
to a flat base as shown on the right in Figure 2.1, which has a pin designed to fit into a corresponding
hole on the phantom for reproducible positioning of the OSL.

Figure 2.1 High-impact polystyrene spherical phantom (left), and phantom base and insert holding
the OSLD within the spherical phantom (right)
2.1.2 RPC Pelvic Phantom
The RPC’s pelvic phantom was used for this study, which was designed for remote audits and
credentialing of institutions for participation in clinical trials. The phantom shell is made of PVC, can
be filled with water to simulate soft tissue, and is made to estimate the average size and shape of
patients and organs of interest in the treatment of the prostate as seen in Figure 2.2.
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Figure 2.2 Axial CT scans of phantom (left) and patient (right) demonstrating similarity of phantom
to patient anatomy
The shell contains polybutylene terephthalate (PBT) – polyester cylinders to simulate the femoral
heads, each containing
ontaining a hollow tube for the insertion of acrylic femoral head rods. There are two
imaging rods made of solid acrylic, and two dosimetric rods, each of which containss a hollow space
for the positioning of a TLD capsule at the level of the target. At tthe
he base of the pelvic phantom, a
large diameter tube allows for the placement of the imaging and dosimetric inserts
inserts,, both locking into
place within the tube,, as seen in Figure 2.
2.3.. For the CyberKnife irradiations, four gold fiducials were
placed along the large tube for motion tracking with the orthogonal x-ray imaging system used during
CyberKnife treatments.

Figure 2.3 RPC pelvic phantom shell (left) with dosimetry (middle) and imaging (right) inserts
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The imaging insert of the phantom contains both a target and organs at risk, made of
materials to approximate patient tissue densities and CT numbers. A spherical nylon ball was used
for the prostate, a polyethylene ball for the bladder, and a cylinder of wax surrounded by a thin
polyethylene tube was used for the rectum and rectal wall. The dosimetry insert is made of highimpact polystyrene, and the cylinder breaks into four quarters for loading dosimeters as seen below in
Figure 2.4. Within the target volume of the dosimetry insert, there are two TLD and it was modified
to hold an additional two OSLD in the axial plane. The insert also contains film in both the coronal
and sagittal planes, which are pricked by pins mounted in the insert in spots unique to the phantom,
and these pin pricks are used for the registration of the film, discussed later in Section 2.6.2.

Figure 2.4 Dosimetry insert split into posterior and anterior half (left), and posterior half split into
two quarters to show positioning of OSLD and TLD (red circles) at the center of the target (right)
2.1.3 Slab Phantom
The energy dependence of OSLD in full phantom conditions had not yet been characterized
by the RPC, so the phantom seen below in Figure 2.5 was used to perform irradiations to determine a
full phantom energy-dependence correction factor for OSLD. The phantom is made of 15 x 15 cm2
slabs of high-impact polystyrene, each 2 cm thick, with the exception of one 3 cm thick slab. One
slab contained a section in the middle that could slide out and hold a TLD at the center. A new
sliding section was made to the exact dimensions of the previous section holding the TLD, but instead
was made to hold an OSLD nano-cassette centered within the slab. A piece of high-impact
polystyrene was then placed on top of the OSLD to eliminate any air gap within the phantom. A
single OSLD was placed at a depth of 10 cm. Beyond the depth of the OSLD, there was 7 cm of
high-impact polystyrene to provide sufficient backscatter. Another 2 cm thick section of the phantom
contained a cylinder bored out of the center to insert an ionization chamber.
12

Figure 2.5 High-impact polystyrene phantom showing section where OSLD placed

2.2 Treatment Planning
2.2.1 Phantom Simulation
The CT images were acquired using a GE LightSpeed RT16 scanner (GE Healthcare,
Waukesha, WI). The phantom shell and dosimetry insert were filled with water, and the acrylic
imaging rods were placed in the femoral heads. The phantom was placed on the imaging couch in the
supine position, in a head first orientation. The lasers were aligned to place the isocenter near the
center of the prostate. The laser lines were marked with tape on the anterior, left, and right sides of
the phantom. Radio-opaque markers (bb’s) were placed at the laser crosshairs to mark isocenter. A
typical MD Anderson prostate protocol was used for the CT simulation, and the resulting images
were imported into the Pinnacle treatment planning system for the three co-planar treatments. The
pelvic phantom was then imaged on a GE LightSpeed RT16 Xtra scanner at St. Luke’s Episcopal
Hospital Radiation Therapy and CyberKnife Facility using the same setup procedure and a similar
scanning protocol, for developing the CyberKnife treatment plan. The resulting images were
imported into Accuray’s MultiPlan (Accuray, Sunnyvale, CA) treatment planning system.
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Figure 2.6 Axial CT image of prostate phantom at the level of simulation isocenter with the target
and critical structures as indicated
An axial slice of the phantom at the level of the ccenter
enter of the target is shown in Figure 2.6.
2.
The bb placement, indicating isocenter, can be seen on the anterior, right and left sides of the
phantom in the image.
2.2.2 Dose Prescription
The dosimetric guidelines for this study are based on the dose prescription and constraints set
by the RPC Prostate IMRT credentialing protocol. The protocol specifies that at least 98% of the
PTV receives a dose of 6 Gy, and a maximum dose of 6.4 Gy may be delivered to less than 2% of the
PTV. The bladder, rectum and
nd femoral heads are the critical normal structures, and must not receive
more than 6.7 Gy. The normal structure constraints are listed in Table 2.1.
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Structure

Dosimetric Constraints
V5.7 Gy < 50%
V6.0 Gy < 35%

Bladder

V6.3 Gy < 25%
V6.7 Gy < 15%
V5.0 Gy < 50%
V5.7 Gy < 35%

Rectum

V6.0 Gy < 25%
V6.3 Gy < 15%

Femoral Heads

Maximum dose ≤ 6.7 Gy

Table 2.1 RPC Prostate IMRT normal tissue constraints
2.2.3 Planning Procedures
Treatment planning was performed on Pinnacle v9.0 (Phillips Medical, Madison, WI) and
MultiPlan v3.5.3 (Accuray, Sunnyvale, CA). The couch was removed from the images, and the
treatment isocenter was identified at the intersection of the simulation bb’s. Contours were created
for the prostate, bladder, rectum and femoral heads manually using the region of interest (ROI) tool.
Contours were also created for the TLD in the target and femoral heads, as well as for the OSLD in
the target. The external tissue was contoured using the auto-contour function. Using guidelines set
by MD Anderson’s Genitourinary (GU) Service, several planning structures were created. The
prostate was expanded by 7 mm in all directions, with the exception of a 5 mm posterior expansion,
to create the PTV. An additional 5 mm margin was added to the PTV to create a structure called
‘PTV expand’. A structure for the normal tissue was created by removing the volume ‘PTV expand’
from the external tissue. Additional planning structures were created, including a 1 cm expansion of
the PTV, which could be used to achieve coverage of the target, and a rectum avoid structure to bring
the dose off the anterior wall of the rectum. The rectum avoid structure was created by subtracting
the structure ‘PTV expand’ from the contoured rectum.
Four treatment plans of increasing angular beam delivery were created for the pelvic phantom
using common dose prescriptions and constraints described in Section 2.2.2.
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2.2.3.1 Four Field Box
Four coplanar beams were created for this plan, each using 18 MV photons. The
anteroposterior (AP) beam had a gantry angle of 0°, a gantry angle of 180° was used for the
posteroanterior (PA) beam, and gantry angles of 90°and 270° were used for the left lateral and right
lateral beams, respectively. The jaws were set to achieve adequate coverage of the PTV, while
minimizing the dose to the normal tissue. The couch and collimator angles were set to 0° for all
beams. The dose grid encompassed the phantom, and used a resolution of 0.4 cm3. The final dose
was computed using the collapsed cone (CC) convolution algorithm.
2.2.3.2 IMRT
The typical beam arrangement for prostate IMRT at MD Anderson uses eight 6 MV photon
coplanar beams, with the following gantry angles: 225°, 260°, 295°, 330°, 30°, 65°, 100°, and 135°.
The couch and collimator angles were set to 0° for all beams. The dose grid encompassed the
phantom and a resolution of 0.4 cm3 was used. Initially, each beam was set to be equally weighted
and unlocked. Direct Machine Parameter Optimization (DMPO) was used for the inverse planning,
and was set to allow the computer to set the field size. The objectives for the plan focused foremost
on achieving target coverage, achieving the dose constraints to the critical structures, and finally, the
normal tissue objective was set to deliver a maximum of half the prescription dose to 1% of the
volume. The plan was normalized to 97% of the prescribed dose to achieve PTV coverage. The final
dose calculation was computed using the CC convolution algorithm.
2.2.3.3 VMAT
Two arcs were created using the dynamic arc beam type in Pinnacle, allowing for variable
gantry rate, MLC leaf speed, and dose rate. The couch angle was set to 0° and 6 MV photons were
used for both arcs. The dose grid covered the entire phantom and used a resolution of 0.4 cm3. Each
beam was given equal weight, with the first arc beginning at a gantry angle of 181° and rotating to
180° in a clockwise (CW) motion with a 30° collimator angle. The second arc rotated from 180° to
181° in a counter-clockwise (CCW) motion with a 330° collimator angle. SmartArc optimization was
used, and the computer was allowed to set the field size. The optimization generated a new control
point every 4 degrees, and the leaf motion was constrained to prevent the MLC from attempting to
move too quickly. The objectives for the plan were similar to those used for the IMRT optimization,
the most important being target coverage, then trying to meet critical structure dose constraints, and
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minimizing the dose to the normal tissue. The plan was normalized to 96% of the prescribed dose to
achieve PTV coverage. Final dose was calculated using the CC convolution algorithm.
2.2.3.4 CyberKnife
Using Accuray’s MultiPlan v3.5.3 inverse treatment planning system, a CyberKnife plan was
created. The CyberKnife Robotic Radiosurgery System (Accuray, Sunnyvale, CA) utilizes a 6 MV
compact linear accelerator mounted on a robotic arm, and delivers pencil beams at discrete nodes
surrounding the patient. The beam can be collimated by using either a set of interchangeable circular
collimators, or the Iris™ Variable Aperture Collimator. The plan for this study used the Iris
collimator, and limited the cone sizes used from 25 mm up to 60 mm. The dose grid encompassed the
phantom, and a high-resolution dose grid was used during the final dose calculation, which performs
calculations for every voxel in the CT image set. The objectives for the plan were the same as those
used for the IMRT optimization, the most important being target coverage and meeting critical
normal structure constraints. A minimum number of MU per beam was set. The ray-tracing
algorithm was used for the final dose calculation, and the plan was normalized to 90% of the
prescribed dose. Sharma et al.22 briefly describes the ray-tracing algorithm method. This dose model
uses a combination of off-axis ratios (OAR), tissue-phantom ratios (TPR), collimator output factors
(OF), and central-axis effective depth calculations to correct for the patient geometry and tissue
heterogeneities.

2.3 Phantom Irradiations
2.3.1 Spherical Phantom Irradiations
Irradiations were performed using the spherical phantom described in Section 2.1.1, to
investigate the angular response of the OSLD under the simplest of circumstances for 6 MV and 18
MV photon beams. The irradiations were delivered on a Varian 21EX linear accelerator (Varian
Medical Systems, Palo Alto, CA) calibrated using the AAPM TG-51 protocol23 and operated in
service mode. The phantom was centered on the central axis (CAX) of the beam, and the top of the
phantom was set to 95 cm SSD. The field size was set to 5 x 5 cm2, and the collimator angle was 0°
throughout the irradiation of this phantom. The monitor units (MU) needed to deliver 100 cGy to the
OSLD was calculated using Equation 2.1:
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Equation 2.1 Linac MU calculation
where D is the prescribed dose per field in cGy, k is the cGy/MU under the reference calibration
conditions. DF is the depth factor (PDD for SSD techniques or TMR for SAD techniques), SC and SP
are the collimator scatter and phantom scatter factors, OAF is the off-axis factor, and AF is an
attenuation factor, representing any beam attenuators such as wedges or trays.
The positioning of the phantom was checked periodically throughout the irradiations. Three
sets of irradiations were performed using the spherical phantom, two coplanar irradiations using beam
energies 6 MV and 18 MV, and one non-coplanar irradiation with a 6 MV photon beam.
The dose delivered to each OSLD was calculated using Equation 2.7. The OSLD calculated
dose was normalized for all edge-on angles to the face-on angle. The dose calculated to each
dosimeter was normalized to the average dose to the dosimeters irradiated at the face-on angle. A
statistical analysis of these normalized doses was performed to determine if the response of the OSLD
at the face-on angle was different from the responses at the edge-on angles. A one-way analysis of
variance (ANOVA) test was performed, which is used to compare the means of two or more groups,
with the normalized dose as the dependent variable and the angle as the factor. The null hypothesis
states that the samples in these multiple groups are drawn from the same population. A p-value less
than α=0.05 indicated that the null hypothesis could be rejected and the group means were
significantly different. After performing the one-way ANOVA, if the null hypothesis was rejected, a
Fisher’s Least Significant Difference (LSD) test was run to determine which means are statistically
significantly different from each other. This test compares the mean of one group with the mean of
another group using a series of t-tests, the null hypothesis stating that the means of the two groups are
equal.
2.3.1.1 Coplanar 6 MV Irradiations
The first set of irradiations were delivered with a 6 MV photon beam. The OSLD response
with the beam incident normally on the face of the dosimeter (face-on) was compared to the response
of the dosimeter at varying beam angles in an edge-on orientation around the dosimeter. The angles
with respect to the OSLD can be seen below in Figure 2.7. The edge-on irradiations were done in 45°
increments around the dosimeter, from 0° to 315°. For the irradiation of the angles on the inferior
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half of the dosimeter (225°, 270°, and 315°), the OSLD was rotated 180° within the phantom to
measure the response of the dosimeter without the influence of the treatment couch and rails.

Figure 2.7 Diagram of OSLD and angles for 6 MV coplanar irradiations. Angles irradiated continue
around bottom half of OSLD in edge-on orientation every 45°.
Three OSLD were irradiated at each angle, and the average response at each angle was normalized to
the average response at the face-on angle. For the face-on irradiation, both the gantry and the couch
were set at 270°. For all other angles, the couch rotation was set to 0° and the gantry was rotated
about the phantom. The setup for the 45° irradiation is shown below in Figure 2.8.

Figure 2.8 Spherical phantom positioned for 45° OSLD irradiations
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2.3.1.2 Coplanar 18 MV Irradiations
The second set of spherical phantom irradiations were performed using an 18 MV photon
beam, and the response of the OSLD in the face-on orientation was compared to the response of
several angles around the dosimeter in the edge-on orientation. The OSLD angles irradiated can be
seen in Figure 2.9. The edge-on irradiations were performed every 90° around the dosimeter.

Figure 2.9 Diagram of OSLD and angles for 18 MV coplanar irradiations
Three OSLD were irradiated at each angle, and the average response for each edge-on angle was
normalized to the average response for the face-on irradiation. The gantry and couch angles used for
the coplanar 6 MV irradiations discussed in Section 2.3.1.1 were also used for this set of irradiations.
For the angle on the inferior half of the dosimeter (270°), the OSLD was again rotated within the
phantom to eliminate the effects of the treatment couch and rails.
2.3.1.3 Non-coplanar 6 MV Irradiations
The final set of spherical irradiations was designed to simulate a cone of beam angles similar
to the angles that might be delivered in a prostate CyberKnife treatment. The irradiations were
performed using a 6 MV photon beam. The response of the dosimeter at varying irradiation angles
was normalized to the response of the OSLD in the face-on orientation. The angles irradiated can be
seen in Figure 2.9. The angles investigated in the coplanar beam orientation ranged from 0° to 180°,
as seen on the left in Figure 2.10. In the non-coplanar beam arrangement, a 90° range of angles
centered about the top of the OSLD were investigated, with irradiations every 15° as seen on the right
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in Figure 2.10. Three OSLD were irradiated at each angle. The couch rotation was set to 0° for all
angles, and the gantry was rotated about the phantom.

Figure 2.10 Diagram of OSLD and angles for 6 MV non-coplanar irradiations
2.3.2 Pelvic Phantom Irradiations
To study the angular dependence of the OSLD in full phantom conditions for treatment plans
of increasing angular beam delivery, the pelvic phantom described in Section 2.1.2 was irradiated.
The four treatment plans of increasing angular beam delivery are discussed in Section 2.2.3,
consisting of three coplanar treatments (4-field box, IMRT, and VMAT) and one non-coplanar
treatment (CyberKnife). The coplanar treatment plans were delivered on a Varian 21EX linear
accelerator calibrated using the AAPM TG-51 protocol. The non-coplanar treatment was delivered
on the CyberKnife G4 Robotic Radiosurgery System at St. Luke’s Radiation Therapy and CyberKnife
facility in Houston, TX as shown below in Figure 2.11. Each plan met the dose prescription and
critical normal tissue constraints outlined in Section 2.2.2, planned to deliver a target dose of 6 Gy.
The OSLD batch 06K10 used in this study was only commissioned for linearity corrections up to a
dose of 3.5 Gy, so the coplanar treatment plans were scaled to deliver a target dose of 3 Gy. The new
OSLD batch, 16K12 was then commissioned at the RPC to higher dose levels, allowing the original
dose prescription to be met. The CyberKnife treatment and the institution trials, discussed later in
Section 2.3.2.1, incorporated the new 16K12 OSLD batch, so the original dose prescription of 6 Gy
was maintained for these deliveries.

21

Figure 2.11 CyberKnife irradiation of pelvic phantom
For the treatment plans delivered on the Varian 21EX linacs, the phantom was positioned at
the head of the couch in the head first, supine orientation. The lasers were aligned to the simulation
isocenter using the bb’s and the tape marks, and the positioning of the phantom was checked
periodically throughout the treatment delivery. The positioning of the phantom for the CyberKnife
treatment delivery was accomplished using the fiducials implanted within the phantom shell and the
CyberKnife’s image guidance system. The positions of the fiducials are at known coordinates within
the phantom. The image guidance system uses two orthogonal fixed x-ray imaging units to image the
phantom before and throughout treatment delivery, and these images are compared to previously
generated digitally reconstructed radiographs (DRRs) to determine the positioning and target location,
and make any necessary adjustments to the phantom position by moving the treatment couch.
Each treatment plan was delivered three times, each time loading new dosimeters into the
phantom before the next irradiation. The dosimeters included in each treatment deliver varied by
plan. For the 4-field treatment, the dosimeters loaded into the phantom included TLD in the target
and femoral heads, and OSLD in the target volume. The same dosimeters were loaded into the
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VMAT and CyberKnife treatments as well. For the IMRT deliveries, the dosimeters included TLD
and OSLD loaded in the same manner as the other treatments, as well as radiochromic film in both
the coronal and sagittal planes through the target volume.
During the delivery of the VMAT treatment plans, the rails of the treatment couch were
moved in and out, as the gantry rotated about the phantom. For the delivery of the first arc, with the
gantry rotating about the phantom in the clockwise direction, the rails were out between the angles
181° and 220°. At this point, the rails were moved in to the center of the couch as the gantry rotated
from 220° to 140°. From 140° to 180°, completing the first arc, the rails were moved back out. The
second arc began at 180° and rotated about the phantom in the counter-clockwise direction, and the
rails were moved in and out during the same angles as for the first arc. This technique was employed
to reduce the effect of the rails on the dose delivered to the phantom.
2.3.2.1 Institution Trials
As an additional check, the RPC pelvic phantom was sent to two institutions for irradiation.
For each institution, the phantom was sent according to RPC credentialing protocol, including
instructions for simulation, planning, and treatment delivery, and the dosimeters traditionally sent
(TLD and radiochromic film). The only change to the standard credentialing process was the
inclusion of two OSLD, batch 16K12, within the dosimetric insert, as they had been placed during all
previous irradiations of the pelvic phantom. One institution performed the RPC credentialing
protocol for prostate IMRT, and the second institution performed a prostate CyberKnife irradiation.
Both of these institution trials used the standard RPC prostate dose prescription and normal structure
constraints.
2.3.3 Energy Correction Irradiations
Using the slab phantom discussed in Section 2.1.3, a set of irradiations was performed to
investigate the energy dependence of the OSLD in full phantom conditions, and determine an energy
correction factor. The irradiations were performed on a Varian 21EX linac using 6 MV and 18 MV
photon beams. A TG-51 calibration was performed in a large water phantom. The surface of the
water in the phantom was set to 100 cm SSD, with a field size of 10 x 10 cm2, gantry angle of 0° and
collimator rotation of 0°. After performing the calibration, the water phantom was replaced with the
slab polystyrene phantom with the same setup conditions as for the calibration. Both the calibration
and the slab phantom irradiation measurements were made with an Exradin A12 (Standard Imaging,
Middleton, WI) ionization chamber calibrated by the MD Anderson Cancer Center ADCL. Within
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the slab phantom, the ion chamber was positioned at a depth of 10 cm. Three readings were taken per
beam energy, delivering 200 MU per reading.
The readings made for each energy by the ion chamber in the slab phantom at a depth of 10
cm were used to calculate the dose rate (cGy/MU) to muscle at depth using the AAPM TG-21
protocol24. The protocol calculates the dose rate to water at the depth of dmax from measurements
made in a non-water phantom. The dose rate was corrected to dose in muscle using a 0.99 correction,
and the depth was corrected from dmax to 10 cm using the %dd10 for the Varian 21EX.
An estimate of the MU needed to deliver 100 cGy to a depth of 10 cm within the polystyrene
phantom was made by using the percent depth dose (%dd) in water information for the linac at the
particular energy. The desired dose was divided by the %dd10 for both 6 MV and 18 MV. Using the
slab with the modification for OSLD, a dosimeter was placed at 10 cm depth within the phantom and
irradiated to the desired MU. Irradiations were performed for both batches 06K10 and 16K12 OSLD.
Five OSLD were irradiated for each batch and energy combination, irradiating 20 nanoDots total.
The response of the OSLD positioned at 10 cm depth within the slab phantom was measured for each
dosimeter. The ratio of the dosimeter response at the investigated energy weighted by the expected
dose delivered to the response from cobalt-60 weighted by its expected dose was found using
Equation 2.2 shown below:
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Equation 2.2 Ratio of dosimeter responses to correct for energy dependence
The terms Avg Corr Rdg, KF, and KL are the same as defined in Section 2.5. The term DE is the
expected dose delivered to the dosimeters at the investigated energies (6 MV and 18 MV), which was
calculated by multiplying the MU delivered, by the dose rate to muscle at a depth of 10 cm as
calculated using TG-21. The terms in the denominator of Equation 2.2 all refer to the OSLD
previously irradiated in cobalt-60 as standards and read during the same session as the OSLD
irradiated in the slab phantom to establish system sensitivity. The expected dose delivered to the
standard dosimeters,  #$!" , was calculated using an RPC spreadsheet that accounts for the decay of
the source, irradiation setup, and length of irradiation. The linearity correction factor for the
dosimeters irradiated to 100 cGy (standards) is defined to be one.
This ratio was calculated for each irradiated dosimeter. Considering setup and calibration
errors, we can assume that the irradiations of two batches per energy were actually like irradiations of
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the same batch twice. This assumption is valid based on the RPC OSLD mini-phantom experience.
The ratios of the dosimeter responses were grouped for the 06K10 and 16K12 batches by energy, and
an average ratio was calculated per energy (10 dosimeter ratios per energy). The inverse of the
averaged ratios for 6 MV and 18 MV was taken to get the energy correction factors for OSLD in full
phantom conditions.

2.4 RPC TLD Dosimetry
The TLD used in this study were double-loaded cylindrical capsules containing LiF TLD-100
powder (Quantaflux, LLC, Dayton, OH) from batch B11, each load containing approximately 20 mg
of powder. The RPC has already extensively studied the characteristics of this batch of TLD. The
correction factors determined by the RPC are used to calculate the absorbed dose to the TLD using
Equation 2.3:
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Equation 2.3 TLD dose calculation
The term Avg Rdg is the average signal measured per unit mass of the powder. The average reading
from the powder is multiplied by S, the system sensitivity, and several correction factors unique to the
TLD batch: KF, KL, and KE. These factors correct for fading (KF), linearity of the response with dose
(KL), and the energy dependence (KE) of the dosimeters.
2.4.1 TLD Batch Correction Factors
The fading of the TL signal is corrected using the following equation:
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Equation 2.4 TLD fading correction factor
where N = 1.3493, a = 1.2815, b = 0.00010885, c = 0.067810, d = 0.071908, and X is the number of
days since irradiation. The TLD are typically read 14 days after irradiation, but no sooner than day
14.
The RPC protocol for calculating the linearity correction is to perform six iterations of the
calculation to arrive at a final linearity correction value. The correction for the linearity of the
response with dose, for a range of doses from 1 to 40 Gy, is calculated using Equation 2.5:
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Equation 2.5 TLD linearity correction
For ‘low dose’ irradiations, the response has been shown to be linear, and the constants for  are as
follows: a = 0, b = -0.000335, and c = 1.1004995. For ‘high dose’ irradiations, the response of the
dosimeter exhibits supra-linearity, and the constants become a = 2.55207e-8, b = -2.22110e-4, and c =
1.064337. The raw dose is calculated using Equation 2.6:
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Equation 2.6 TLD raw dose calculation
where the terms Avg Rdg, S, and KF are the same as those discussed previously.
The energy correction factors have been measured for each batch of TLD for a range of beam
energies for several of the anthropomorphic QA phantoms by the RPC. Energy correction factors for
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Co, 6 MV, and 18 MV photon beams are 1, 1.03, and 1.07, respectively.

2.4.2 System Sensitivity
The dosimetry system is the combination of the dosimeters, phantom, and the reader. The
system must be calibrated for each reading session because the reader may experience changes in
sensitivity, which is monitored by reading “standards” and “controls”. The standard dosimeters are
irradiated to a known dose from a cobalt-60 unit, and these dosimeters are read at the beginning and
end of a reading to determine the system sensitivity for the session. The system sensitivity, S, is
defined as the expected dose delivered to the standard dosimeters, divided by the average reading, as
well as fading and linearity corrections. The control dosimeters are also irradiated by a cobalt-60
unit, to a different known dose, and are read at the beginning, end, and periodically throughout the
session. The purpose of reading the controls is to check the constancy of the system, and track
changes in sensitivity over time.

2.5 RPC OSLD Dosimetry
The OSLD used in this study were nanoDot™ dosimeters from the InLight® OSL system
(Landauer, Inc., Glenwood, IL). The nanoDot dosimeter contains a 5 mm diameter disk-shaped
sensitive volume of Al2O3:C, 0.2 mm thick. The disk is enclosed in a light-tight plastic case shown in
Figure 2.12, measuring 10 x 10 x 2 mm3. The position of the sensitive volume is indicated on the
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case by the circle with the center marked by the cross hairs. Each dosimeter has a unique barcode
that is scanned prior to being read, and allows for the recording of the associated counts.

Figure 2.12 nanoDot OSLD from Landauer, Inc.
The dosimeters are created in batches, and sent to the RPC where the characteristics of the
batch and each dosimeter are carefully studied. The dosimeters used in this study came from batches
06K10, and 16K12, named according to RPC convention. The dose to the OSLD is calculated using
Equation 2.7:
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Equation 2.7 OSLD dose calculation
The term Avg Corr Rdg is the average counts from the reader, accounting for depletion of the signal,
multiplied by the element correction factor (ECF), as shown below in Equations 2.8 and 2.9. The
element correction factor is discussed in Section 2.5.1.
      · 
Equation 2.8 Element corrected average reading
Each dosimeter is read three times in a row, making n = 3 in Equation 2.9, and all dosimeters from an
irradiation session are read in the same reading session.
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Equation 2.9 Readings averaged and depletion corrected
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The system sensitivity, S, described in Section 2.4.2, is determined by the same method for OSLD as
for TLD. The average corrected reading is multiplied by the system sensitivity factor, and several
batch correction factors (KF, KL, and KE). These batch correction factors are similar in meaning to the
correction factors used for TLD dosimetry, but the calculation methods differ.
2.5.1 Element Correction Factor
The sensitivity of an individual OSLD varies compared to the population of OSLD within the
batch of dosimeters, and is corrected for in the dose calculation by the element correction factor
(ECF). Each OSLD within a batch are irradiated to a known dose and then read. The response of a
single dosimeter at the particular dose level is then divided by the average response of the entire
population of dosimeters within the batch, resulting in the ECF for that particular OSLD. The ECF is
determined at a dose of 25 cGy, and verified at other dose levels. The sensitivity of OSLD have been
shown to change with accumulated dose, as discussed in Section 1.3.2, but the RPC has verified that
for accumulated doses of less than 10 Gy, the average ECF over cycles of irradiation and annealing
compared to the first ECF determined for the dosimeter are within 0.6% 25. No dosimeter used in this
study received an accumulated dose greater than 10 Gy.
2.5.2 OSLD Batch Correction Factors
The fading of the OSL signal after irradiation is corrected using Equation 2.10 for both
batches 06K10 and 16K12:
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Equation 2.10 OSLD fading correction factor
where d is the number of days since irradiation. The RPC OSL dosimetry protocol requires that the
dosimeters be read no sooner than five days post-irradiation.
The correction for the linearity of the response is calculated using Equation 2.11, which is the
same as the equation for TLD, but with different constants and the raw dose is calculated in Equation
2.12 using the average reading that has been corrected by the ECF. The RPC protocol for calculating
the linearity correction is to perform six iterations of the calculation to arrive at a final linearity
correction value.
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Equation 2.11 OSLD linearity correction
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Equation 2.12 OSLD raw dose calculation
As discussed in Section 1.3.2, the linearity of the response of the dosimeter changes with dose. The
linearity correction varies between batches. For the 06K10 batch, the OSLD were commissioned and
a linearity correction factor was found for doses up to 3.5 Gy. The response of the dosimeter is linear
in this dose region, and the constants are a = 0, b = -0.00011579, and c = 1.0116. The commissioning
of the OSLD batch 16K12 measured linearity beyond what was studied for the previous batch. For
doses up to 15 Gy, the response of the 16K12 dosimeters is supra linear and the constants are a =
8.34622e-8, b = -2.67355e-4, and c = 1.0259.
The energy correction factors have been studied for both batches of OSLD under reference
point geometry, for use in calculating doses from OSLD irradiated in the RPC mini-phantoms. The
energy correction factors for the nanoDot dosimeters have not yet been studied under full phantom
conditions. As described in Section 2.3.3, irradiations were performed to determine energy correction
factors for the OSLD in full phantom.
2.5.3 microStar™ Reader
The microStar™ Reader (Landauer, Inc., Glenwood, IL), shown in Figure 2.13, is currently
used by the RPC to read OSLD, and was used for this study. The reader is connected to a computer,
which is used to control the reader and record data from the dosimeters into a database. The reader
uses an array of 38 LED to stimulate the dosimeter, and operates in CW-OSL mode as described in
Section 1.3.3. The LED are set to expose the detector for 7 seconds, according to RPC protocol. A
‘strong beam’ uses all 38 LED for reading low dose dosimeters, and a ‘weak beam’ uses 6 LED for
reading dosimeters with high doses; a single LED illuminates the dosimeter before readout to
determine the dose range6. The signal from dosimeters that have been irradiated to greater than 200
cGy saturate the optical detector circuits when illuminated with the strong beam, but using the weak
beam, the dosimeters can receive a dose up to about 15 Gy before the optical detector is saturated15.
The light produced by the LED bank in the reader is filtered by an OG-515 (Melles Griot,
Rochester, NY) band-pass filter. Prior to reaching the PMT, the stimulation and luminescence
photons are differentiated using a combination of Schott BG-12 (Schott, Mainz, Germany) and Hoya
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B-370 (Hoya, San Jose, CA) colored glass filters. The LED and OG-515 filter combination has a
peak transmission near 530 nm, and the combination of the PMT filters have a transmission peak at
385 nm26.

Figure 2.13 microStar reader, adapter, and control computer
Before reading the OSLD, the reader is turned on and allowed to warm up at least 30 minutes
prior to the session. Several quality control checks are performed on the reader, measuring the
electrical noise of the system, the counts measured from just the LED, and the counts measured from
a calibration source in the detector. The system sensitivity is determined and monitored according to
the procedure described in Section 2.4.2. To begin reading the OSLD, the barcode of the dosimeter is
scanned and it is inserted into the adapter shown in Figure 2.13. The adapter holds the nanoDot in
place within the drawer of the reader, and when the drawer is shut, the adapter opens the dosimeter to
expose the active volume to the light source. The counts measured by the PMT are recorded, and the
OSLD can be removed from the reader.
2.5.4 Signal Depletion
The finite decrease in charge stored by the dosimeter with each reading was referred to in
Section 1.3.2, and RPC OSL dosimetry includes a correction to account for this signal depletion. The
depletion correction for the mth reading (DCm) is calculated using Equation 2.13:
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Equation 2.13 OSLD depletion correction
where a = -5.148e-6, b = -1.277e-3, c = 1, and for a dosimeter read three times, m = {0…2}.
2.5.5 Optical Bleaching
The optical bleaching (annealing) of the OSLD at RPC is performed using the cabinet shown
below in Figure 2.14. Within the cabinet, there are four 54-watt fluorescent bulbs; two bulbs are
fixed at the top of the cabinet and two are positioned at the bottom. To remove any UV photons from
the light, a filter is placed around each bulb. Positioned centrally between the top and bottom light
sources lies a clear acrylic shelf on which the OSLD are placed. The dosimeters are opened, and the
active volume is exposed to the light for 24 hours before they are closed and removed from the box.

Figure 2.14 Cabinet for optical bleaching of OSLD at the RPC

2.6 RPC Film Dosimetry
Radiochromic film is favorable for measuring relative dose distributions because of their high
spatial resolution, insensitivity to visible light, they are nearly tissue equivalent, and they color
directly, eliminating the need for processing. The image formation occurs as a dye-forming or
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polymerization process, and the image is stable over a range of temperatures. The humidity during
irradiation also has little impact on the film27.
Gafchromic EBT2 film (Ashland, Wayne, NJ) was used in this study, from lot number
A0521102 with an expiration date of May 2013. The RPC uses radiochromic film as a part of the
remote audit program, and has already investigated the dose response of this lot of film and
performed a film calibration for the dose range of 0 to 30 Gy. The dose-response curve generated by
the RPC for this batch of film fits the third-order polynomial shown below in Equation 2.14,
establishing a relationship between dose and optical density (OD):
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Equation 2.14 Calibration curve for Gafchromic EBT2 film, lot # A05261102
For each IMRT irradiation in this study, the pieces of film were cut from the same sheet using a
template, and all sheets of film were from the same film lot. One piece was cut for the coronal film,
and the sagittal film was cut in two parts. Each piece of film was marked for orientation. The care
and evaluation of the film was performed according to the recommendations of AAPM TG-55, which
include storing the film in a dark and dry place at room temperature, visually inspecting the film
before irradiation, careful handling of the film, and reading the film at least 48 hours after irradiation
to minimize the effects of self-development27.
The active layer of the EBT2 film is situated between two polyester layers, making it possible
to be submerged in water for short time periods, and includes a yellow marker dye to minimize
differences in film responses due to small variations in thickness of this layer. This marker dye also
has the benefit of making the EBT2 film less sensitivity to ambient light. When the film is irradiated,
the elements in the active layer react and form a blue polymer that appears green due to the presence
of the yellow marker dye. The irradiated film has an absorption peak at 636 nm, and 585 nm.
According to the manufacturer, the film is designed for a wide dose range (1 cGy to 40 Gy), and has
an effective atomic number of 6.84, demonstrating a difference in response of about 10% in the keV
to 6 MV photon energy range. A recent study investigating the energy dependence and dose response
of the EBT2 films found that the energy dependence of the film was lower than that suggested by the
manufacturer, showing that the response of the film varied by approximately 4.5% over an energy
range of 75 kVp to 18 MeV photons28. This study also reported that the self-development of the film
was the fastest during the first 48 hours after the film was irradiated.
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2.6.1 Film Scanning
To evaluate the dose distribution measured, the films were scanned using a CCD100
Microdensitometer (Photoelectron Corporation, Lexington, MA) as shown below in Figure 2.15. The
scanner uses an LED light bed, with a wavelength of 665 nm, and a CCD camera placed above the
film to measure and record the transmission of light. The height of the CCD was set so that the
camera focused on a 200 x 200 mm2 area where the films would be placed, and the remaining area of
the light was covered with a black mask. This system is contained within a cabinet to prevent
measurement of room light. A blank piece of film from the same lot was scanned and used to
measure the ‘flat field’, and then a grid of known size and spacing was scanned to assign a spatial
calibration. Following these calibrations, the films from the IMRT irradiations were scanned in a
consistent orientation. The coronal film was scanned, and then the two pieces of the sagittal film
were placed together and scanned. The images were saved as 16-bit .FIT files.

Figure 2.15 Setup of microdensitometer used for film scanning
33

2.6.2 Registration
The measured dose distribution from the film is compared to the reported dose distribution
from the treatment planning system (TPS), and to do this, the film and the plan must be registered to
the same phantom coordinate system. Using a MATLAB (The MathWorks, Inc., Natick, MA)
program known as the Computational Environment for Radiotherapy Research (CERR) (J.O. Deasy
and Washington University, St. Louis, MO), the treatment plan can be registered to the phantom
coordinate system. From the TPS, the plan, CT image set, composite dose information, and structures
are all exported in DICOM-RT format into CERR. On the CT images, a set of registration points are
identified, which registers the plan to the phantom. Using another MATLAB program, RPCFILM,
the films can be registered to the phantom coordinate system. The .FIT files created after scanning
the film, as discussed in Section 2.6.1, are opened in RPCFILM. The phantom type and number are
identified, and the pinpricks are identified on the image. The location of the pinpricks are unique to
each phantom, and this registers the film to the phantom coordinate system. After both the film and
the treatment plan have been registered to the phantom coordinate system, RPCFILM evaluates the
goodness of fit and calculates RMS error values for the film registration and plan registration, called
‘RMS Error’ and ‘RMS 3D’, respectively. To minimize error, the RPC prefers an ‘RMS Error’ of 0.3
mm or less for one piece of film, such as the coronal film in this study, or 0.5 mm or less for two
pieces of film, such as the sagittal films in this study. The limit for ‘RMS 3D’ is set at 1 mm.
The dose-response curve for the film batch is then used to calculate the measured film dose
from the OD values. The film doses are then normalized to the TLD dose measured in the PTV. For
this study, film analysis was performed only for the three IMRT irradiations as well as for the two
institution trials (one IMRT, one CyberKnife). For each irradiation, the films were normalized to the
PTV TLD doses, as well as to the corrected PTV OSLD doses and then compared, as discussed in
later sections.

2.7 Dosimetric Evaluation
To evaluate the ability of the OSLD to measure on average the same dose as the TLD, the
TLD and OSLD dose measurements from the pelvic phantom irradiations were compared in several
ways. The absolute doses from the TLD and OSLD, the dose profiles normalized by the TLD and
OSLD doses, and the gamma analysis of the film normalized to both TLD and OSLD were compared.
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2.7.1 Absolute Dose
For the pelvic phantom irradiations, the dose measured in the target volume for the TLD and
the OSLD were compared. The locations of the TLD and OSLD within the target can be seen below
in Figure 2.16. The doses measured by the two TLD within the target were calculated using the
method described in Section 2.4, and then averaged. The dose measured by the two PTV OSLD were
calculated using the method described in Section 2.5, averaged, and then multiplied by a correction
factor obtained from the spherical phantom for the appropriate irradiation. The OSLD dose
multiplied by the correction factor is referred to as the corrected OSLD dose. The TLD dose was
compared to the OSLD dose, as stated in the hypothesis. A ratio of TLD dose to corrected OSLD
dose for each pelvic phantom irradiation was calculated, and the average TLD to OSLD dose ratio
was calculated. The TLD dose within the femoral heads was not compared to any OSLD doses, as
there were no OSLD placed within the structure.

Figure 2.16 Diagram of inferior view of the dosimetry insert showing positions of TLD and OSLD
active volumes within the target
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2.7.2 Dose Profiles
Using the RPCFILM program, dose profiles through the PTV were obtained for both the
coronal and sagittal films. For the coronal films, dose profiles were recorded in the lateral and
superior-inferior directions. The lateral profile was taken through the PTV, and the superior-inferior
profile was taken through the PTV and the bladder. On the sagittal films, dose profiles were recorded
in the anterior-posterior (AP) and superior-inferior directions. The AP profile was taken through the
PTV as well as through the rectum. The superior-inferior profile included the dose through the PTV
and through the bladder. The superior-inferior dose profile for the sagittal films was offset from the
center in the AP direction by 2 mm to avoid the gap where the two pieces of the sagittal film were
positioned together for scanning. The film was sampled every 0.3 mm to create the dose profiles, and
a 3 mm moving average was used to smooth the data obtained for the profiles.
The dose profiles were created after the film was normalized to the TLD target doses and the
corrected OSLD target doses. Each profile was plotted displaying the dose calculated by the TPS, the
normalized film dose, and either the TLD dose or the corrected OSLD dose. The dose profiles
resulting from both the TLD and OSLD normalized doses were compared.
2.7.3 Gamma Analysis
Gamma analysis is a quantitative method described by Low et al.29 for comparing dose
distributions measured by film to those generated by the treatment plan, using the measured
distribution as the reference information. This technique evaluates the dose difference between
measured and calculated, and the distance to agreement (DTA), combining the comparisons into a
single numerical index called the gamma (γ) index. A set of criteria for dose difference and DTA are
established for acceptance, each having equal significance in the calculation of the index. The
acceptance criteria for dose difference and DTA form an ellipsoid surface, with the measurement
point at the origin. For each pixel, the dose difference and DTA are calculated and a vector is formed
from the origin to the calculated point. If the magnitude of the normalized vector is less than or equal
to one, the calculated point lies within the ellipsoid, passing the criteria with γ ≤ 1.
For this study, the Matlab program RPCFILM was used to perform the gamma analysis for
each plane of film within the phantom. The criteria established for the RPC pelvic phantom is 7%
dose difference and 4 mm DTA (7%/4 mm) for both the sagittal and coronal films, with at least an
85% pixel pass rate. RPCFILM includes a masking tool which allows for the designation of areas on
the film to not be included in the analysis, such as pin pricks, the junction of the two sagittal films, or
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any other film imperfections or artifacts. An example of area masking on a sagittal film can be seen
below in Figure 2.17. RPC protocol for the pelvic phantom analysis is to use a 10 x 10 cm2 area of
the film for evaluation.

Figure 2.17 Masks applied to a sagittal film before gamma analysis
As discussed in Section 2.6.2, the films are normalized to the TLD target dose before analysis
is performed. For this study, the films were also normalized to the corrected OSLD target dose and
an additional gamma analysis was completed. The gamma results from the TLD normalization and
OSLD normalization were compared.

37

Chapter 3 Results and Discussion
3.1 Treatment Planning
Four treatment plans of increasing angular beam delivery were developed as discussed in
Section 2.2, each meeting the dose prescription and normal tissue constraints outlined in the RPC
prostate IMRT credentialing protocol. For the three treatment plans developed in Pinnacle, the PTV,
prostate, bladder, rectum, and femoral heads are represented by the purple, blue, yellow, green, and
pink contours, respectively. The CyberKnife plan developed in MultiPlan displays the PTV, prostate,
bladder, rectum contours as orange, coral, light blue, and green. The femoral heads are displayed as
the pink and dark blue contours, representing the left and right femoral heads. The four treatment
plans and their dose-volume histograms (DVH) are displayed below for the same CT slice, at the
level of the simulation isocenter. As discussed in Section 2.3.2, the three coplanar treatment plans
delivered a target dose of 3 Gy, while the CyberKnife plan delivered a target dose of 6 Gy.
3.1.1 Four Field Box
The isodose lines and the DVH generated by the 4-field treatment plan in the pelvic phantom
can be seen below in Figure 3.1. The prescription dose of 3 Gy covers 99% of the PTV and 100% of
the prostate volume. The normal tissue constraints are met, but the 4-field treatment does deliver a
higher dose to the critical structures than the subsequent plans.

Figure 3.1 Four field isodose coverage (left) and DVH (right) for the prostate phantom. The PTV,
prostate, bladder, rectum, and femoral heads are displayed as purple, blue, yellow, green, and pink,
respectively.

38

3.1.2 IMRT
The IMRT treatment plan for the pelvic phantom isodose plot and DVH can be seen in Figure
3.2. The target prescription dose of 3 Gy covers 99% of the PTV and achieves complete coverage of
the prostate volume. As seen in the DVH, the dose to the femoral heads, bladder, and rectum are all
lower than for the 4-field box treatment.

Figure 3.2 IMRT isodose coverage (left) and DVH (right) for prostate phantom. The PTV, prostate,
bladder, rectum, and femoral heads are displayed as purple, blue, yellow, green, and pink,
respectively.
3.1.3 VMAT
The isodose coverage and DVH generated for the pelvic phantom VMAT treatment plan can
be seen below in Figure 3.3. The prescription dose of 3 Gy covers 99% of the PTV and 100% of the
prostate, meeting the dose prescription outlined previously. Similar to the IMRT treatment, the doses
received by the normal structures are lower compared to the 4-field treatment.
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Figure 3.3 VMAT isodose coverage (left) and DVH (right) for prostate phantom. The PTV, prostate,
bladder, rectum, and femoral heads are displayed as purple, blue, yellow, green, and pink,
respectively.
3.1.4 CyberKnife
The isodose lines and DVH generated by the CyberKnife plan developed in MultiPlan for the
pelvic phantom can be seen below in Figure 3.4. The prescription dose of 6 Gy covers 99.8% of the
PTV and 100% of the prostate volume. The bladder and rectal dose were higher for the CyberKnife
treatment than for either the IMRT or VMAT treatment plans.

Figure 3.4 CyberKnife isodose coverage (left) and DVH (right) for prostate phantom. The PTV,
prostate, bladder, and rectum are displayed as orange, coral, light blue, and green. The left and right
femoral heads are represented by the pink and blue contours, respectively.
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3.2 Phantom Irradiations
3.2.1 Spherical Phantom Irradiations
The irradiations of the spherical phantom were carried out according to the setup described in
Section 2.3.1. The MU needed to deliver 100 cGy to a depth of 5 cm on CAX, for a field size of 5 x
5 cm2 for photon beams of energy 6 MV and 18 MV were calculated using Equation 2.1, and are
shown below in Equations 3.1 and 3.2, respectively. For both beam energies, there is no off-axis
factor (OAF) and there were no trays or wedges attenuating the beam. The depth factor used for these
calculations was Tissue Maximum Ratio (TMR), since the phantom irradiation was performed using
the SAD technique. The MU necessary to deliver the desired dose at 6 MV was calculated to be 114
MU, and 101 MU at 18 MV.
 

100 .KL
1.03 MNO
PQ

· 0.905 · 0.962 · 0.983

 114 

Equation 3.1 MU calculation for 6 MV spherical phantom irradiation
 

100 .KL
1.067 MNO
PQ

· 1.001 · 0.943 · 0.982

 101 

Equation 3.2 MU calculation for 18 MV spherical phantom irradiation
The dose delivered to each OSLD was calculated using Equation 2.7. The normalized OSLD
responses for the coplanar 6 MV spherical phantom irradiations can be seen below in Figure 3.5. The
error bars for each data point represent the standard error (SE). The null hypothesis of the one-way
ANOVA test was rejected (p-value = 0.000), showing that the mean of at least one angle response
was different from the other mean responses. The Fisher’s LSD test determined that the response of
the dosimeter at the face-on angle was statistically significantly different from all other angles at the
α=0.05 level
An additional ANOVA was performed including only the edge-on angular responses, and the
resulting p-value of 0.124 shows that the null hypothesis cannot be rejected. The responses at these
angles cannot be from different populations, therefore the responses can be grouped together.
Knowing this, the normalized responses for all edge-on angles were averaged, and the average was
calculated to be 0.961 and is indicated on the graph as the red horizontal line.
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Figure 3.5 OSLD response for coplanar 6 MV spherical phantom irradiations
For the coplanar 18 MV spherical phantom irradiations, the normalized OSLD responses can
be seen below in Figure 3.6. The error bars represent the standard error for each angular response.
The noticeably larger error for the average dose at 180° is due to one of the three OSLD irradiated at
that angle being either a bad OSL, or there was an error in the irradiation of the dosimeter, so that
data was not included in the calculation of the average dose, nor the standard error. The responses of
the dosimeters at the varying angles were found to be statistically significantly different (p-value =
0.006) after running one-way ANOVA. The Fisher’s LSD test showed that the OSLD response for
the face-on angle was statistically significantly different from the edge-on angular responses. A
second ANOVA test, comparing only the edge-on angular responses showed that there is no
difference in response between the angles (p-value = 0.425). The average edge-on normalized OSLD
response, indicated by the red horizontal line on the graph, was calculated to be 0.981.
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Figure 3.6 OSLD response for coplanar 18 MV spherical phantom irradiations
The normalized OSLD responses from the non-coplanar 6 MV spherical phantom
irradiations, specific to CyberKnife, can be seen in Figure 3.7. The error bars for each data point
represent the standard error. A statistically significant difference was found between the different
angles irradiated (p-value = 0.000), and the Fisher’s LSD test determined that the response of the
dosimeter at the face-on angle was statistically significantly different from the responses for all
remaining angles. An additional ANOVA was performed, excluding the face-on response, and the
resulting p-value of 0.006 shows that the null hypothesis can be rejected and the responses of these
angles are from different populations and the means of the angular responses are not equal. The
average edge-on dosimeter response was still calculated, and found to be 0.963 as shown by the red
horizontal line on the graph.
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Figure 3.7 OSLD response for non-coplanar 6 MV spherical phantom irradiations
For each spherical phantom irradiation, the average normalized response of the dosimeters in
the edge-on orientation was determined. The averaged doses measured by the dosimeters in the edgeon orientation relative to the doses measured when the beam was incident normally on the face of the
dosimeter for the coplanar spherical phantom irradiations were 0.961 and 0.981, for 6 MV and 18 MV
photon beams, respectively. These results demonstrate an under-response of the OSLD of
approximately 4% for 6 MV, and 2% for 18 MV. The coplanar spherical phantom irradiation results
are in agreement with the data published by Kerns et al.3, which demonstrated a decrease in the
OSLD response of 4% for 6 MV photon beams parallel to the surface of the dosimeter. The angular
response at 6 MV of the nanoDot dosimeter normalized to the dosimeter response at 0° reported by
Kerns can be seen below in Figure 3.8, demonstrating the approximately 4% decrease in response of
the dosimeter for the edge-on irradiations (90° and 270°). It is important to note that the orientation
of the nanoDot within the pelvic phantom for the Kerns study is not the same as the orientation used
in this study, and as such, only the responses at 0°, 90°, and 270°are applicable for comparison.

44

Figure 3.8 Angular response of OSLD at 6 MV normalized to response at 0°, error bars represent the
coefficient of variation (Kerns et al.), copied with permission from AAPM.
The decrease in response of 2% for the 18 MV coplanar spherical phantom irradiations
observed in this study is slightly higher than the decrease in response of 3% for the edge-on
irradiations reported by Kerns, which can be seen below in Figure 3.9. The increased response
observed in this study for 18 MV coplanar photon beams compared to the Kerns study, going from an
under-response of 3% to 2%, could be attributed to differences in the phantoms used. The decrease in
response of 2% for the OSLD was measured in the small, spherical phantom from this study, whereas
the under-response of 3% reported by Kerns was measured in the RPC’s pelvic phantom. The scatter
conditions provided by the two phantoms are different, and as discussed in Section 1.1, the scatter
component is important to the dose deposited in the OSLD. While the small differences in responses
observed at 18 MV (2 % vs. 3%) may be due to the phantoms, the responses may be the same within
experimental uncertainties. However, the trend of an increase in response from 6 MV to 18 MV
photon beams that was shown by Kerns is supported by the results of this study.
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Figure 3.9 Angular response of OSLD at 18 MV normalized to the response at 0°, error bars
represent the coefficient of variation (Kerns et al), copied with permission from AAPM.
The averaged dose measured by the dosimeters normalized to the dose measured in the faceon orientation for the non-coplanar 6 MV spherical phantom irradiations was 0.963, demonstrating a
4% under-response of the dosimeter. However, the ANOVA results indicate that the normalized
responses at all the investigated non-face-on angles are not from the same population, so averaging
the responses may not be an appropriate method of determining the angular response of the OSLD.
The inverse of the average normalized responses was then taken to determine the angular
correction factors to be used for adjusting the OSLD measured dose for the pelvic phantom
irradiations. The angular correction factors calculated can be seen below in Table 3.1. These factors
were applied to the OSLD measured dose from the pelvic phantom irradiations, as shown in Section
3.3 for the absolute dose, dose profiles, and gamma analysis comparisons.
Angular Correction

Stdev

Coplanar 6 MV

1.040

0.007

Coplanar 18 MV

1.019

0.004

Non-coplanar 6 MV

1.038

0.009

Table 3.1 Angular correction factors and standard deviations from spherical phantom irradiations
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3.2.2 Pelvic Phantom Irradiations
Irradiations of the RPC pelvic phantom were carried out according to the setup discussed in
Section 2.3.2. Each treatment plan was delivered three times, and the doses measured from both the
TLD and the OSLD for each coplanar treatment plan (4-field, IMRT, VMAT) can be seen below in
Figure 3.10. The error bars for each data point represent the standard error. The TLD dose was
calculated using Equation 2.3, and the dose delivered to the OSLD was calculated using Equation 2.7.
The doses measured by the two TLD in the PTV were averaged, as well as the doses from the two
OSLD in the PTV, to represent a single dose delivered to the center of the PTV in the phantom. The
OSLD measured dose, not corrected for angular dependence, is shown to be consistently lower than
the doses measured by the TLD in the pelvic phantom for the coplanar irradiations. The underresponse of the OSLD compared to the TLD is shown to be greater for the 6 MV IMRT and VMAT
irradiations, than for the 18 MV 4-field irradiations, consistent with the spherical phantom results
shown in Section 3.2.1. The average percent differences between the TLD measured dose and
uncorrected OSLD measured dose for the 4-field, IMRT, and VMAT irradiations were calculated to
be 1.9%, 3.0%, and 3.3%, respectively.

Coplanar Pelvic Phantom Irradiations
330
325
320

Dose (cGy)

315
TLD

310

OSLD

305
300
295
290
285

Figure 3.10 TLD and OSLD doses from 3 Gy coplanar pelvic phantom irradiations
The doses measured by the TLD and OSLD in the PTV of the pelvic phantom for the
CyberKnife irradiations performed can be seen below in Figure 3.11. The data for the TLD doses and
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OSLD doses are offset from each other in the x-direction for clear visualization of the data points and
their associated errors. The error bars for each dose represent the standard error. Again, the TLD and
OSLD doses were calculated using Equations 2.3 and 2.7, respectively. The doses measured by the
two target TLD were averaged to represent a single dose delivered to the center of the prostate. The
same averaging was done with the two target OSLD doses. In the pelvic phantom, the OSLD, not
corrected for angular dependence, once again under-responded for the non-coplanar treatment as
compared to the response of the TLD. The average percent difference between the TLD measured
dose and uncorrected OSLD measured dose was calculated to be 1.1% for the three CyberKnife
irradiations. However, the doses measured by the OSLD, not corrected for angular dependence, for
the three CyberKnife irradiations were closer to the doses measured by the TLD than expected. Many
of the beams in the CyberKnife deliveries were from angles superior and inferior to the edge-on
angles, so the angular correction is not as great as for the gantry based, coplanar deliveries.

Non-Coplanar Pelvic Phantom Irradiations
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CyberKnife_1

CyberKnife_2

CyberKnife_3

Figure 3.11 TLD and OSLD doses from the three 6 Gy non-coplanar pelvic phantom irradiations
As discussed in Section 2.3.2.1, the prostate phantom was sent to two different institutions to
evaluate the response of the OSLD in the phantom. One institution delivered a standard prostate
IMRT treatment, and the second institution delivered a CyberKnife treatment. The doses measured
by the target TLD and OSLD in the pelvic phantom for both institution trials can be seen below in
Figure 3.12. The error bars for each dose represent the standard error. The doses measured by the
TLD were calculated using Equation 2.3, and the dose measured by the OSLD was calculated using
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Equation 2.7. The doses from the two TLD were averaged, and the doses from the two OSLD were
averaged to represent a single dose to the PTV. For each institution trial, the uncorrected OSLD dose
was lower than the TLD dose. The percent differences between the TLD measured dose and
uncorrected OSLD measured dose were 4.4% and 3.4% for the IMRT and CyberKnife institution
trials, respectively. For the CyberKnife trial, the OSLD measured dose was much lower compared to
the TLD measured dose and consistent with the response expected from the non-coplanar spherical
phantom irradiations, but contrary to the CyberKnife results shown in Figure 3.11 (1.1% difference as
compared to 3.4%). As mentioned previously, the majority of the beam angles for the CyberKnife
irradiation were incident on the OSLD at angles superior and inferior to the edge-on angles, which
would result in a lower angular correction than for the coplanar deliveries, but this was not observed
for the CyberKnife trial.

Pelvic Phantom Trial Irradiations
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Figure 3.12 TLD and OSLD doses from 6 Gy institution trials
Comparison of the TLD and OSLD measured doses, as well as the corrected OSLD doses
using the values presented in Table 3.1, is performed later in Section 3.3.1.
3.2.3 Energy Correction Irradiations
The irradiations necessary to determine the energy correction factors for OSLD in full
phantom conditions were performed as described in Section 2.3.3. Ion chamber measurements in the
polystyrene slab phantom were made at a depth of 10 cm, the depth where the OSLD would later be
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placed, for the calculation of dose rate and dose delivered to the OSLD. Three ion chamber readings
were made for the two beam energies, and the results can be seen below in Table 3.2.
Beam Energy

Reading 1 (nC)

Reading 2 (nC)

Reading 3 (nC)

6 MV

26.69

26.68

26.68

18 MV

31.85

31.84

31.84

Table 3.2 Ion chamber measurements in slab phantom at depth of 10 cm for 6 MV and 18 MV
photon beams
These ion chamber readings were used to calculate the dose rate to water at a depth dmax using
the TG-21 protocol, and making corrections for the dose rate to muscle at a depth of 10 cm. The dose
for 6 MV, and 1.027
rate to water at dmax was calculated to be 1.016 RST
UV

RST
UV

for 18 MV. The TG-21

worksheets for the two beam energies can be found in the Appendix, in Section 5.1. The calculations
for the dose rate to muscle at a depth of 10 cm for beam energies 6 and 18 MV can be seen below in
Equations 3.3 and 3.4, respectively.
W@XYMZ[ )6 10 .A  1.016

.KL
66.3
.KL
· 0.99 ·
 0.667

100


Equation 3.3 Dose rate to muscle at a depth of 10 cm for 6 MV photon beam
W@XYMZ[ )6 10 .A  1.027

80.7
.KL
.KL
· 0.99 ·
 0.821
100



Equation 3.4 Dose rate to muscle at a depth of 10 cm for 18 MV photon beam
The MU estimated to deliver 100 cGy to a depth of 10 cm in the phantom was calculated for
6 MV and 18 MV, and can be seen in Equations 3.5 and 3.6, respectively. These MU settings were
used to deliver approximately the desired dose to the OSLD at depth in the polystyrene phantom, as
the %dd data is specified to water.
 

100 .KL
 151 
66.3⁄100

Equation 3.5 MU calculation to deliver approximately 100 cGy to OSLD for 6 MV photon beam
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100 .KL
 124 
80.7⁄100

Equation 3.6 MU calculation to deliver approximately 100 cGy to OSLD for 18 MV photon beam
The ratio of the dosimeter response at the designated energy to the response for cobalt-60 was
calculated as described in Section 2.3.3. Standard dosimeters were read for both the 06K10 and
16K12 OSLD batches, for which the expected dose delivered is 100 cGy. The average corrected
reading (Avg Corr Rdg) for the 06K10 standards was calculated to be 434,931, which represents the
raw PMT counts that have been depletion corrected and multiplied by the ECF for each dosimeter, as
described in Section 2.5. The average corrected reading for the 16K12 standards was calculated to be
366,210. The fading correction factor (KF) was calculated for all OSLD using Equation 2.10, and the
fading correction factor for the standards from batch 06K10 can be seen below in Equation 3.7. The
fading correction factor for batch16K12 standards, which were read 7 days after irradiation, was
calculated using this same equation to be 1.009064.
 

1
 1.007945
1.005 · 6*.?1

Equation 3.7 Fading correction factor for dosimeters read 6 days post-irradiation
The expected dose delivered to the standard dosimeters was calculated using the RPC spreadsheet,
and was found to be 100.095 cGy.
For each dosimeter irradiated, the average corrected reading, fading correction factor, and
linearity correction factor was calculated. The linearity correction factor was calculated using
Equation 2.11 for both 06K10 and 16K12 dosimeters. The expected dose delivered to the standard
dosimeters for 6 MV and 18 MV was calculated as shown below in Equations 3.8 and 3.9,
respectively.
 P\  151  · 0.667

.KL
 100.72 .KL


Equation 3.8 Expected dose delivered to OSLD for 6 MV photon beam
8] P\  124  · 0.821

.KL
 101.8 .KL


Equation 3.9 Expected dose delivered to OSLD for 18 MV photon beam
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The ratio of dosimeter responses, calculated using Equation 2.2, was calculated for each
irradiated OSLD. The ratios of the five 06K10 OSLD irradiated at 6 MV, and the ratios of the five
16K12 OSLD irradiated at 6 MV were averaged to produce an energy correction factor for the OSLD
at 6 MV. The same averaging was done for the five 06K10 dosimeters and five 16K12 dosimeters
irradiated at 18 MV. The inverse of the two ratios, one for each of the two beam energies, was taken
to calculate the energy correction factors. The energy correction factors for OSLD in full phantom
conditions, calculated for photon beam energies 6 MV and 18 MV can be seen below in Table 3.3.
These energy correction factors were used in the calculation of OSLD dose as described in Section
2.5.
Beam Energy

KE

Stdev

6 MV

1.02

0.010

18 MV

1.08

0.011

Table 3.3 Energy correction factors for OSLD in full phantom conditions
The calculated energy correction factors for OSLD in full phantom conditions are very close
to the correction factors for TLD in full phantom, 1.03 and 1.07 for 6 MV and 18 MV photon beams,
respectively. A decrease in response of the OSLD for the energies of 6 MV and 18 MV was
observed, with a higher decrease for the 18 MV beams, as also observed for TLD. This result is
consistent with the results of Viamonte et al. 13 in that there was a decrease in response of the OSLD
at higher energies. Viamonte showed that for dosimeters calibrated in a 60Co beam, there was an
observed decrease in sensitivity of 4%, although a 4% decrease in response was observed in this study
for neither 6 MV nor 18 MV.

3.3 Dosimetric Evaluation
3.3.1 Absolute Dose
Four treatment plans were developed and delivered to the RPC pelvic phantom. The three
coplanar treatment plans included a 4-field box, IMRT, and VMAT. The one non-coplanar plan was
a CyberKnife treatment. The phantom was irradiated three times for each plan to determine the
ability of the OSLD to measure an equivalent dose to the TLD dose measurements. Each delivery
included two TLD in the femoral heads, two TLD in the PTV, and two OSLD in the PTV. The
OSLD in the PTV were located adjacent to the TLD, offset from the center of the target by
approximately the same distance as the TLD. Only the average doses measured by the TLD and
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OSLD in the PTV are reported and compared. The doses measured by the OSLD were calculated
using Equation 2.7, and the TLD measured doses were calculated using Equation 2.3. The ratio of the
average TLD dose to the average OSLD dose was calculated for each plan. The ratios of the TLD
dose to uncorrected OSLD dose for the coplanar treatment plans can be seen below in Table 3.4. The
average TLD to OSLD dose ratio and standard deviation for all coplanar deliveries in the table below
was calculated to be 1.028 ± 0.008. With the exception of the dose ratio for the treatment delivery ‘4
field_1’ the OSLD dose differs from the TLD dose by greater than 1%.
TLD Dose (cGy)

OSLD Dose (cGy)

TLD/OSLD

4 field_1

317.0

313.9

1.010

4 field_2

317.2

309.2

1.026

4 field_3

319.3

312.7

1.021

IMRT_1

297.6

289.7

1.027

IMRT_2

298.8

289.1

1.034

IMRT_3

298.0

289.1

1.031

VMAT_1

320.4

308.3

1.039

VMAT_2

321.7

311.5

1.033

VMAT_3

319.4

310.1

1.030

Table 3.4 TLD to OSLD dose ratios for coplanar treatment plans
The angular correction factors determined from the spherical phantom irradiations, shown in
Table 3.1, were applied to the OSLD calculated doses. The correction factor for coplanar 18 MV
treatments of 1.019 was applied to the 4-field measured OSLD doses. The coplanar 6 MV correction
factor of 1.040 was applied to the measured doses for the IMRT and VMAT deliveries. The ratios of
the TLD dose to angular corrected OSLD dose for the coplanar treatment plans can be seen below in
Table 3.5. The average TLD to corrected OSLD dose ratio and standard deviation for the coplanar
deliveries was calculated to be 0.995 ± 0.006. For all coplanar treatment deliveries, the corrected
OSLD dose is within 1% of the dose measured by the TLD, with the exception of ‘IMRT_1’.
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TLD Dose (cGy)

Corr OSLD Dose (cGy)

TLD/Corr OSLD

4 field_1

317.0

319.9

0.991

4 field_2

317.2

315.1

1.007

4 field_3

319.3

318.6

1.002

IMRT_1

297.6

301.3

0.988

IMRT_2

298.8

300.7

0.994

IMRT_3

298.0

300.7

0.991

VMAT_1

320.4

320.6

0.999

VMAT_2

321.7

324.0

0.993

VMAT_3

319.4

322.5

0.990

Table 3.5 TLD to corrected OSLD dose ratios for coplanar treatment plans
The ratio of the TLD measured dose to the OSLD measured dose, without the angular
correction, for the non-coplanar CyberKnife treatment deliveries can be seen below in Table 3.6. The
average TLD to OSLD dose ratio and standard deviation for the non-coplanar treatments was
calculated to be 1.011 ± 0.003. Each delivery resulted in an OSLD dose that differed from the TLD
dose by approximately 1%.

CK_1
CK_2
CK_3

TLD Dose (cGy)
620.3
617.7
621.8

OSLD Dose (cGy)
612.4
613.3
613.5

TLD/OSLD
1.013
1.007
1.013

Table 3.6 TLD to OSLD dose ratios for CyberKnife treatments
From the spherical phantom irradiations, the angular dependence correction factor of 1.038
for the non-coplanar 6 MV deliveries, specific to CyberKnife treatments, was applied to the OSLD
doses. The ratios of the TLD measured dose to the angular corrected OSLD dose for the CyberKnife
deliveries can be seen below in Table 3.7. The average TLD to corrected OSLD dose ratio and
standard deviation was calculated to be 0.974 ± 0.003. Each CyberKnife treatment delivery resulted
in a difference between the TLD dose and OSLD dose by greater than 1%.
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TLD Dose (cGy)
620.3
617.7
621.8

CK_1
CK_2
CK_3

Corr OSLD Dose (cGy)
635.7
636.6
636.8

TLD/Corr OSLD
0.976
0.970
0.976

Table 3.7 TLD to corrected OSLD dose ratios for CyberKnife treatments
The response of the OSLD compared to the TLD for the two institution trials was calculated
by taking the ratio of the TLD dose to the OSLD dose, as done for the previous irradiations. The
ratios of the doses for the institution trials, one IMRT delivery and one CyberKnife delivery, can be
seen below in Table 3.8. The average TLD to OSLD dose ratio and standard deviation was calculated
to be 1.040 ± 0.008. Each trial showed a response difference between the TLD and OSLD of greater
than 1%.
TLD Dose (cGy)

OSLD Dose (cGy)

TLD/OSLD

IMRT

615.6

589.1

1.045

CyberKnife

675.9

653.5

1.034

Table 3.8 TLD to OSLD dose ratios for the institution trials
Using the angular dependence correction factors employed previously, the corrected OSLD
doses were calculated. The OSLD dose for the IMRT trial was multiplied by the angular correction
factor of 1.040, and the CyberKnife trial OSLD dose was multiplied by the correction factor 1.038.
The ratios of TLD dose to corrected OSLD dose for the two institution trials can be seen in Table 3.9.
The average TLD to corrected OSLD dose ratio and standard deviation was calculated to be 1.001 ±
0.007. Both the IMRT and CyberKnife institution trials had OSLD angular corrected doses within
1% of the TLD measured doses.
TLD Dose (cGy)

Corr OSLD Dose (cGy)

TLD/Corr OSLD

IMRT

615.6

612.1

1.006

CyberKnife

675.9

679.0

0.995

Table 3.9 TLD to corrected OSLD dose ratios for the institution trials
For each set of irradiations, with the exception of the three CyberKnife irradiations shown in
Table 3.7, the applied angular correction factors corrected the OSLD dose to within 1% of the
measured TLD dose, with very low error. The 6 MV non-coplanar angular correction factor, when
applied to the OSLD measured dose from the CyberKnife institution trial, adequately corrected the
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OSLD dose, so it is unclear as to why the correction factor failed to scale the OSLD dose
appropriately for the other CyberKnife irradiations. CyberKnife treatments are very nonhomogeneous in nature, so it is possible that even with the TLD and OSLD oriented in the phantom
to be very close together, there could be large dose differences between the two types of dosimeters,
making it difficult to compare the angular corrected OSLD dose to the TLD dose. The films present
in the phantom at irradiation could be used to determine if large dose differences within the target
were present, which was not possible for the three CyberKnife treatments in this study as there were
no films included in the phantom for these irradiations. Another complication to the CyberKnife dose
comparison is that the plans between different institutions could vary widely. The angular delivery of
the MU from different plans could be very different, and result in differences in dose deposited in the
OSLD.
The outcome of the absolute dose comparisons show that the coplanar 6 MV and 18 MV
angular correction factors, when applied to the measured OSLD doses, yield equivalent results to the
TLD measured doses, and can be used for the purpose of credentialing with the RPC’s
anthropomorphic QA phantoms.
3.3.2 Dose Profiles
The phantom irradiations contained film in the coronal and sagittal planes through the target
for the three IMRT treatment deliveries, as well as for both institution trials, for the evaluation of the
agreement between planned and measured doses. Each film was normalized to the TLD target doses,
and again for the angular corrected OSLD target doses. The coronal film is evaluated by taking
profiles through the PTV in both the lateral and superior-inferior directions. The sagittal film is
evaluated by taking profiles through the PTV in the AP and superior-inferior directions. Selected
profiles from the second IMRT delivery, ‘IMRT_2’, can be seen in the figures below. The lateral
profile taken from the coronal film, normalized to the TLD and corrected OSLD doses can be seen in
Figures 3.13 and 3.14, respectively. The AP profile recorded from the sagittal film, normalized to the
TLD doses can be seen in Figure 3.15, and the profile from the film normalized to the corrected
OSLD doses can be seen in Figure 3.16. The drop in measured dose at the center of the AP profile
from the sagittal film is due to the gap where the edges of the two pieces of the film come together.
The superior-inferior profiles taken from the sagittal film normalized to the TLD target doses and the
angular corrected OSLD target doses can be seen in Figures 3.17 and 3.18, respectively. All other
profiles for the IMRT and institution trial deliveries can be seen in the Appendix, in Section 5.2. The
profiles display the institution reported doses from the TPS, the measured dose from the film
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normalized to target dosimeter doses, and the point doses from the dosimeters in the target. These
dose profiles were not evaluated for quantitative results, but rather as a qualitative analysis of the
ability of the OSLD to measure equivalent dose to the TLD and provide similar results when
normalizing film, when an angular dependence correction is made to the OSLD dose.
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- Coronal Plane
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Figure 3.13 Lateral dose profile in coronal plane from IMRT_2 as planned by TPS and measured by
film normalized to target TLD dose
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Figure 3.14 Lateral dose profile in coronal plane from IMRT_2 as planned by TPS and measured by
film normalized to corrected target OSLD dose
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TLD Normalized AP Profile - Sagittal Plane
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Figure 3.15 AP dose profile in sagittal plane from IMRT_2 as planned by TPS and measured by film
normalized to target TLD dose
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Figure 3.16 AP dose profile in sagittal plane from IMRT_2 as planned by TPS and measured by film
normalized to corrected target OSLD dose
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TLD Normalized Superior Inferior Profile
- Sagittal Plane
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Figure 3.17 Superior-inferior dose profile in sagittal plane from IMRT_2 as planned by TPS and
measured by film normalized to target TLD dose
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Figure 3.18 Superior-inferior dose profile in sagittal plane from IMRT_2 as planned by TPS and
measured by film normalized to corrected target OSLD dose
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For each film presented, the films normalized to the angular corrected OSLD target doses
appear almost identical to the films normalized to the TLD target doses. While the normalized film
profiles may not match up well to the institution reported profiles, as seen in the superior-inferior
profiles from the sagittal films in Figures 3.17 and 3.18, the aim of this study is not to compare the
OSLD doses or OSLD normalized film to the institution values, but rather to compare the TLD with
the OSLD. These results validate that the film can be normalized to the angular corrected OSLD
target doses for the purposes of credentialing with the RPC’s anthropomorphic QA phantoms.
3.3.3 Gamma Analysis
Another method by which the ability of the OSLD, when a correction for the angular
dependence is made, to measure equivalent dose to TLD measurements is evaluated was by
comparing gamma analysis results for film normalized to both TLD doses and OSLD doses, as
described in Section 2.7.3. The percent of pixels passing the 7%/4 mm gamma criteria for the three
IMRT treatment deliveries is shown in Table 3.10. The pass rates for each film in the phantom
normalized to the target TLD doses can be seen next to the pass rates for the films normalized to the
angular corrected OSLD target doses. The percentage of pixels passing the same gamma criteria for
the two institution trials can be seen in Table 3.11. For the purpose of this study, it is not necessary or
important that the films pass the RPC gamma criteria of greater than 85% of pixels passing, but the
significance rests in the ability of the OSLD normalized films to pass at the same rate as the TLD
normalized films. For the three IMRT deliveries and the two institution trials, the gamma pass rates
for the films normalized to both the TLD and the corrected OSLD are very close, if not the same.
The low passing rates for the three IMRT deliveries can be attributed to the low dose delivered to the
film. The RPC experience has shown that for a target dose of 3 Gy, the noise properties dominate the
film, making accurate results difficult to obtain.
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TLD Gamma

OSLD Gamma

Pass Rate

Pass Rate

Coronal

82%

83%

Sagittal

80%

81%

Coronal

88%

88%

Sagittal

85%

84%

Coronal

82%

82%

Sagittal

75%

75%

Film
IMRT_1

IMRT_2

IMRT_3

Table 3.10 Percent of pixels passing gamma analysis for IMRT deliveries in the coronal and sagittal
films for a criteria of 7%/4 mm for film normalized to TLD dose and corrected OSLD dose
TLD Gamma

OSLD Gamma

Pass Rate

Pass Rate

Coronal

100%

100%

Sagittal

99%

99%

Coronal

93%

93%

Sagittal

94%

94%

Film
IMRT

CyberKnife

Table 3.11 Percent of pixels passing gamma analysis for institution trials in the coronal and sagittal
films for 7%/4 mm criteria for film normalized to TLD dose and corrected OSLD dose
The distribution maps, both color scale and binary, for the sagittal and coronal films with
pixels passing the 7%/4 mm gamma criteria for the irradiation IMRT_2 can be seen below in Figure
3.19 through Figure 3.26. The gamma results are shown for both the TLD normalized films and the
films normalized by the angular corrected OSLD doses. The gamma analysis results for the
remaining IMRT deliveries and the institution trials are shown in the Appendix, in Section 5.3.
The gamma results for the coronal films from the second IMRT irradiation can be seen
below, Figure 3.19 shows the coronal film normalized to the TLD target doses and Figure 3.20 shows
the same film normalized to the corrected OSLD target doses. The same results, with the binary
display of pixels passing can be seen below, Figure 3.21 is the result for the TLD normalized film and
Figure 3.22 is the result for the angular corrected OSLD normalized film. The areas of pixels passing
the gamma criteria for both the TLD and OSLD normalized films appear essentially the same.
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Figure 3.19 IMRT_2 color scale gamma results for coronal film normalized to target TLD dose

Figure 3.20 IMRT_2 color scale gamma results for coronal film normalized to corrected target OSLD
dose
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Figure 3.21 IMRT_2 binary gamma results for coronal film normalized to target TLD dose

Figure 3.22 IMRT_2 binary gamma results for coronal film normalized to corrected target OSLD
dose
The gamma results for the sagittal films from the second IMRT irradiation can be seen below,
Figure 3.23 shows the sagittal film normalized to the TLD doses and Figure 3.24 shows the same film
normalized to the corrected OSLD doses. The sagittal film gamma results shown in the binary
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display, passing pixels appear blue and failing pixels appear green, can be seen below. Figure 3.25 is
the result for the TLD normalized film and Figure 3.26 is the result for the angular corrected OSLD
normalized film. The areas of pixels passing the gamma criteria for both the TLD and OSLD
normalized films appear the same, with few variations.

Figure 3.23 IMRT_2 color scale gamma results for sagittal film normalized to target TLD dose

Figure 3.24 IMRT_2 color scale gamma results for sagittal film normalized to corrected target OSLD
dose
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Figure 3.25 IMRT_2 binary gamma results for sagittal film normalized to target TLD dose

Figure 3.26 IMRT_2 binary gamma results for sagittal film normalized to corrected target OSLD
dose
The results from the gamma analysis, comparing the pass rates and pixel distributions of the
TLD normalized films and the corrected OSLD normalized films, demonstrate that the analysis of the
films when normalized to the angular corrected OSLD target doses yields equivalent results to the
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TLD normalized films. The films normalized to the angular corrected OSLD target doses can be used
for the purpose of credentialing with the RPC’s anthropomorphic QA phantoms.
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Chapter 4 Conclusions
4.1 Conclusion
This study investigated the angular dependence of the nanoDot OSL dosimeters in the RPC
pelvic phantom to effectively utilize the OSLD as a replacement for the TLD in the anthropomorphic
QA phantoms. The replacement of TLD in the QA phantoms with OSLD would be beneficial to the
RPC. The benefits of OSLD include shorter waiting periods post-irradiation, simpler and quicker
readout procedures, minimal energy dependence, signal is not destroyed when they are read, allowing
them to be read multiple times, and they are not affected by environmental changes. As the miniphantom portion of the remote audit system has already made the switch to OSLD, the switch from
TLD to OSLD in the anthropomorphic phantoms would further streamline the remote audit process
and greatly improve efficiency.
OSLD were irradiated within a small, spherical polystyrene phantom to study the angular
dependence of the dosimeters under the simplest of conditions for both 6 MV and 18 MV photon
beams. The results of these irradiations lead to the determination of angular correction factors of
1.040 and 1.019 for coplanar treatments with beam energies 6 MV and 18 MV, respectively, and a
correction factor of 1.038 for non-coplanar treatments at 6 MV, specific to CyberKnife treatments.
Within the experimental uncertainties, the correction factors at 6 MV for the coplanar and noncoplanar treatments are essentially the same.
The irradiations of the RPC pelvic phantom included TLD, OSLD, and film for the IMRT
and institution trials. The film was included in the select treatments in order to validate the use of
OSLD dose, when the angular dependence has been corrected, to normalize the film for obtaining
dose profiles or performing gamma analysis, and to show that the OSLD normalized film yields the
same results as film normalized by the TLD doses. Comparisons of the absolute doses measured by
the TLD and OSLD, the dose profiles generated by normalized films, and gamma analysis of the
normalized films were all performed. The ratio of the doses measured by the TLD to the corrected
OSLD measured dose was calculated to be 0.995 ± 0.006 for the coplanar treatment deliveries. The
ratio of the TLD measured doses to the angular corrected OSLD doses for the non-coplanar treatment
deliveries was calculated to be 0.974 ± 0.003. The institution trials served as a method to verify the
ability of the angular correction factors established from the spherical phantom irradiations to correct
the OSLD dose to within 1% of the TLD measured dose. The average ratio of the TLD to corrected
OSLD dose for the two institution trials was calculated to be 1.001 ± 0.007. For all irradiations, the
angular dependence correction factors determined in this study effectively corrected the OSLD
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measured dose to within 1% of the TLD measured dose, with the exception of the three CyberKnife
treatment deliveries.
Our hypothesis, that the incorporation of OSLD into the RPC phantom will measure on
average an equivalent dose measurement as compared to the existing TLD measurements within
±1%, regardless of the angular dependence of the OSLD, was not supported. Based on the results of
the study, the OSLD can be effectively used as a replacement for the TLD in the phantoms and
measure an equivalent dose within 1%, only if the OSLD angular dependence is first corrected.
Caution is advised regarding the use of the angular dependence correction factor for the
OSLD determined in this study for non-coplanar CyberKnife treatment deliveries. The discrepancies
between the data from the three CyberKnife treatments delivered at St. Luke’s compared to the
CyberKnife irradiation for the institution trial were considerable, and the correction factor that
worked so well when applied to the trial data, did not yield good results when applied to the original
CyberKnife data. In addition, the statistical analysis of the OSLD responses from the non-coplanar 6
MV spherical phantom irradiations showed that averaging the normalized responses might not be the
appropriate method of establishing the angular dependence correction factor. A single correction
factor for the established angular dependence of the OSLD for CyberKnife irradiations may not be
possible due to the high dose gradients and inherent inhomogeneities of the treatment, and that
CyberKnife credentialing may need to be performed according to the current method of using TLD as
the absolute dosimeter. If a switch from TLD to OSLD is pursued for CyberKnife credentialing using
the anthropomorphic QA phantoms, further investigation of an appropriate angular dependence
correction factor must be performed.

4.2 Future Work
The results of this study indicate that the modification of the collection of pelvic phantoms at
the RPC could begin to include OSLD as a replacement for the TLD for coplanar treatment deliveries
in both the PTV as well as in the femoral heads. An investigation of other anthropomorphic QA
phantoms for which the inclusion of OSLD would be most appropriate, and how the modifications
would be made could also be done. With the incorporation of the OSLD into the phantoms, the
characterization of the energy correction factors for the OSLD in full phantom conditions must be
completed for additional beam energies, both photon and electron beams.
It is also clear from this study that further research regarding the OSLD response for noncoplanar treatments, such as CyberKnife, and a possible correction factor for the OSLD angular
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dependence in these situations, must be pursued. This further study of the dosimeter response for
non-coplanar CyberKnife treatments might be more feasible when the RPC has credentialed a greater
number of CyberKnife treatments using the existing method of mailable phantoms with TLD, but also
including OSLD in the target volume and collecting data on the measured doses.
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Chapter 5 Appendix
5.1 TG-21 Worksheets
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5.2 Dose Profiles
5.2.1 IMRT_1
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Figure 5.1 Lateral dose profile in coronal plane from IMRT_1 with film normalized to TLD dose
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Figure 5.2 Lateral dose profile in coronal plane from IMRT_1 with film normalized to corrected
OSLD dose
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Figure 5.3 AP dose profile in sagittal plane from IMRT_1 with film normalized to TLD dose
IMRT_1
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Figure 5.4 AP dose profile in sagittal plane from IMRT_1 with film normalized to corrected OSLD
dose
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TLD Normalized Superior Inferior Profile
- Sagittal Plane
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Figure 5.5 Superior-inferior dose profile in sagittal plane from IMRT_1 with film normalized to TLD
dose
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Figure 5.6 Superior-inferior dose profile in sagittal plane from IMRT_1 with film normalized to
corrected OSLD dose
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5.2.2 IMRT_3
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Figure 5.7 Lateral dose profile in coronal plane from IMRT_3 with film normalized to TLD dose
IMRT_3
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Figure 5.8 Lateral dose profile in coronal plane from IMRT_3 with film normalized to corrected
OSLD dose
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IMRT_3

TLD Normalized AP Profile - Sagittal Plane
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Figure 5.9 AP dose profile in sagittal plane from IMRT_3 with film normalized to TLD dose
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Figure 5.10 AP dose profile in sagittal plane from IMRT_3 with film normalized to corrected OSLD
dose
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IMRT_3

TLD Normalized Superior Inferior Profile - Sagittal
Plane
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Figure 5.11 Superior-inferior dose profile in sagittal plane from IMRT_3 with film normalized to
TLD dose
IMRT_3
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Figure 5.12 Superior-inferior dose profile in sagittal plane from IMRT_3 with film normalized to
corrected OSLD dose
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5.2.3 CyberKnife Trial
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Figure 5.13 Lateral dose profile in coronal plane from CyberKnife trial with film normalized to TLD
dose
CyberKnife Trial
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Figure 5.14 Lateral dose profile in coronal plane from CyberKnife trial with film normalized to
corrected OSLD dose
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CyberKnife Trial
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Figure 5.15 AP dose profile in sagittal plane from CyberKnife trial with film normalized to TLD
dose
CyberKnife Trial
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Figure 5.16 AP dose profile in sagittal plane from CyberKnife trial with film normalized to corrected
OSLD dose
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CyberKnife Trial
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Plane
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Figure 5.17 Superior-inferior dose profile in sagittal plane from CyberKnife trial with film
normalized to TLD dose
CyberKnife Trial
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Figure 5.18 Superior-inferior dose profile in sagittal plane from CyberKnife trial with film
normalized to corrected OSLD dose
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5.2.4 IMRT Trial
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Figure 5.19 Lateral dose profile in coronal plane from IMRT trial with film normalized to TLD dose
Trial IMRT
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Figure 5.20 Lateral dose profile in coronal plane from IMRT trial with film normalized to corrected
OSLD dose
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Figure 5.21 AP dose profile in sagittal plane from IMRT trial with film normalized to TLD dose
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Figure 5.22 AP dose profile in sagittal plane from IMRT trial with film normalized to corrected
OSLD dose
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Figure 5.23 Superior-inferior dose profile in sagittal plane from IMRT trial with film normalized to
TLD dose
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Figure 5.24 Superior-inferior dose profile in sagittal plane from IMRT trial with film normalized to
corrected OSLD dose
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5.3 Gamma Analysis
5.3.1 IMRT_1 Coronal Films

Figure 5.25 IMRT_1 color scale gamma results for coronal film normalized to TLD dose

Figure 5.26 IMRT_1 color scale gamma results for coronal film normalized to corrected OSLD dose
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Figure 5.27 IMRT_1 binary gamma results for coronal film normalized to TLD dose

Figure 5.28 IMRT_1 binary gamma results for coronal film normalized to corrected OSLD dose
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5.3.2 IMRT_1 Sagittal Films

Figure 5.29 IMRT_1 color scale gamma results for sagittal film normalized to TLD dose

Figure 5.30 IMRT_1 color scale gamma results for sagittal film normalized to corrected OSLD dose
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Figure 5.31 IMRT_1 binary gamma results for sagittal film normalized to TLD dose

Figure 5.32 IMRT_1 binary gamma results for sagittal film normalized to corrected OSLD dose
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5.3.3 IMRT_3 Coronal Films

Figure 5.33 IMRT_3 color scale gamma results for coronal film normalized to TLD dose

Figure 5.34 IMRT_3 color scale gamma results for coronal film normalized to corrected OSLD dose
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Figure 5.35 IMRT_3 binary gamma results for coronal film normalized to TLD dose

Figure 5.36 IMRT_3 binary gamma results for coronal film normalized to corrected OSLD dose
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5.3.4 IMRT_3 Sagittal Films

Figure 5.37 IMRT_3 color scale gamma results for sagittal film normalized to TLD dose

Figure 5.38 IMRT_3 color scale gamma results for sagittal film normalized to corrected OSLD dose
92

Figure 5.39 IMRT_3 binary gamma results for sagittal film normalized to TLD dose

Figure 5.40 IMRT_3 binary gamma results for sagittal film normalized to corrected OSLD dose
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5.3.5 CyberKnife Trial Coronal Films

Figure 5.41 CyberKnife trial color scale gamma results for coronal film normalized to TLD dose

Figure 5.42 CyberKnife trial color scale gamma results for coronal film normalized to corrected
OSLD dose
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Figure 5.43 CyberKnife trial binary gamma results for coronal film normalized to TLD dose

Figure 5.44 CyberKnife trial binary gamma results for coronal film normalized to corrected OSLD
dose
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5.3.6 CyberKnife Trial Sagittal Films

Figure 5.45 CyberKnife trial color scale gamma results for sagittal film normalized to TLD dose

Figure 5.46 CyberKnife trial color scale gamma results for sagittal film normalized to corrected
OSLD dose
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Figure 5.47 CyberKnife trial binary gamma results for sagittal film normalized to TLD dose

Figure 5.48 CyberKnife trial binary gamma results for sagittal film normalized to corrected OSLD
dose
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5.3.7 IMRT Trial Coronal Films

Figure 5.49 IMRT trial color scale gamma results for coronal film normalized to TLD dose

Figure 5.50 IMRT trial color scale gamma results for coronal film normalized to corrected OSLD
dose
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Figure 5.51 IMRT trial binary gamma results for coronal film normalized to TLD dose

Figure 5.52 IMRT trial binary gamma results for coronal film normalized to corrected OSLD dose
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5.3.8 IMRT Trial Sagittal Films

Figure 5.53 IMRT trial color scale gamma results for sagittal film normalized to TLD dose

Figure 5.54 IMRT trial color scale gamma results for sagittal film normalized to corrected OSLD
dose
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Figure 5.55 IMRT trial binary gamma results for sagittal film normalized to TLD dose

Figure 5.56 IMRT trial binary gamma results for sagittal film normalized to corrected OSLD dose
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